We have carried out a randomised controlled trial of this intervention delivered when women attended for final routine mammogram at age 67–70 years on the UK National Health Service Breast Screening Programme.,We carried randomised controlled trial intervention delivered women attended final routine mammogram age 67–70 UK National Health Service Breast Screening Programme.,G0000000|C0206243|G0000000|C2587213|C0008976|C0886296|C1705822|C0043210|C1456498|C0205088|C0205547|C0024671|C0001779|G0000000|C0041700|C3245503|C0018684|C0557854|C0006141|C0220908|C1709697
Patients with recurrent or metastatic squamous cell carcinoma of the esophagus who had not previously been treated palliative chemotherapy for metastatic disease were eligible.,Patients recurrent metastatic squamous cell carcinoma esophagus treated palliative chemotherapy metastatic disease eligible.,C0030705|C2945760|C0036525|C1182670|C0007634|C0007097|C0014876|C1522326|C0587605|C0013216|C0036525|C0012634|C1548635
"Of the 77 patients recruited to the study, 71 were evaluable for response.","Of 77 patients recruited study, 71 evaluable response.",G0000000|C0450371|C0030705|G0000000|C0557651|C0450371|C1516986|C0871261
"Women who were pregnant or breastfeeding, had a confirmed or suspected immunosuppressive or immunodeficient condition, an allergic disease likely to be exacerbated by any component of the vaccine, or previously received HPV vaccination or 3-O-desacyl-4’-monophosphoryl lipid A were excluded.","Women pregnant breastfeeding, confirmed suspected immunosuppressive immunodeficient condition, allergic disease exacerbated component vaccine, received HPV vaccination 3-O-desacyl-4’-monophosphoryl lipid A excluded.",C0043210|C0549206|C0006147|C0521093|C0332147|C0021081|C0021051|C0012634|C0700624|C0012634|C0436331|C0449432|C0042210|C1514756|C0021344|C0042196|G0000000|C0023779|G0000000|C1554077
Exclusion criteria were; past history of pelvic radiotherapy or abdominal surgery and diarrhea before the beginning of this study.,Exclusion criteria were; history pelvic radiotherapy abdominal surgery diarrhea study.,C0680251|C0243161|G0000000|C0019664|C0030797|C0034619|C0000726|C0038894|C0011991|C0557651
571 healthy children aged 1-6 years: 282 (mean (SD) age 4.6 (1.5) years) in the intervention group and 289 (mean (SD) age 4.4 (1.5) years) in the control group.,571 healthy children aged 1-6 years: 282 (mean (SD) age 4.6 (1.5) years) intervention 289 (mean (SD) age 4.4 (1.5) years) control group.,C1442061|C3898900|C0008059|C0001779|G0000000|C0439234|C1442061|C0444504|G0000000|C0001779|G0000000|G0000000|C0439234|C0886296|C1442061|C0444504|G0000000|C0001779|G0000000|G0000000|C0439234|C0243148|C0441833
"Exclusion criteria were good levator function, absent Bell’s phenomenon, and abnormal ocular motility.","Exclusion criteria levator function, absent Bell’s phenomenon, abnormal ocular motility.",C0680251|C0243161|G0000000|C0031843|C0332197|G0000000|C1882365|C0205161|C0015392|C0007608
Recurrent patients were eligible if the last dose of postoperative adjuvant chemotherapy had been received at least 180 days before the start of the study.,Recurrent patients eligible dose postoperative adjuvant chemotherapy received 180 days start study.,C2945760|C0030705|C1548635|C0178602|C0032790|C0001551|C0013216|C1514756|C1442061|C0439228|C0439659|C0557651
A total of 108 patients who were undergoing an excisional biopsy for non-palpable breast lesions requiring pathologic diagnosis were randomly assigned to the ROLL group (n = 56) and wire-guided localization group (n = 52).,A total 108 patients undergoing excisional biopsy non-palpable breast lesions requiring pathologic diagnosis randomly assigned ROLL (n = 56) wire-guided localization (n = 52).,G0000000|C0439175|C1442061|C0030705|G0000000|C0728940|C0005558|C1518422|C0006141|C0221198|G0000000|C1521733|C0011900|G0000000|C1516050|G0000000|G0000000|C0181089|C0475264|G0000000
"Children were ineligible if they: were clinically stable on a medication regimen for BP-I; diagnosed with schizophrenia or schizoaffective disorder, a pervasive developmental disorder, anorexia nervosa, bulimia nervosa, obsessive-compulsive disorder, substance dependence, symptoms of mania that were attributable to a general medical condition or secondary to use of medications or general medical condition including neurologic disease, diabetes mellitus, thyroid dysfunction, or renal dysfunction that might be adversely affected by lithium; had clinically significant abnormal laboratory assessments that could influence the efficacy or safety of lithium or would complicate interpretation of study results; had evidence of serious homicidal/suicidal ideation or active hallucinations and delusions such that in the treating physician's opinion it would not be appropriately safe for the subject to participate in this study; or had concomitant prescription of over-the-counter medication or nutritional supplements that would interact with lithium or affect the participant’s physical or mental status.","Children ineligible they: clinically stable medication regimen BP-I; diagnosed schizophrenia schizoaffective disorder, pervasive developmental disorder, anorexia nervosa, bulimia nervosa, obsessive-compulsive disorder, substance dependence, symptoms mania attributable medical condition secondary medications medical condition including neurologic disease, diabetes mellitus, thyroid dysfunction, renal dysfunction adversely lithium; clinically abnormal laboratory assessments influence efficacy safety lithium complicate interpretation study results; evidence homicidal/suicidal ideation active hallucinations delusions treating physician's opinion appropriately safe subject participate study; concomitant prescription over-the-counter medication nutritional supplements interact lithium affect participant’s physical mental status.",C0008059|C1512714|G0000000|G0000000|C0205360|C0013227|C0040808|C0037623|C0011900|C0036341|G0000000|C0012634|C0205391|C0458003|C0012634|C0003123|G0000000|C0006370|G0000000|G0000000|C0012634|C0439861|C0011546|C0683368|C0338831|C0596130|C0199168|C0012634|C0027627|C0013227|C0199168|C0012634|C0332257|C0205494|C0012634|C0011847|G0000000|C0040132|C0031847|C0022646|C0031847|G0000000|C0023870|G0000000|C0205161|C0022877|C1261322|C4054723|C1280519|C0036043|C0023870|C0231242|C0459471|C0557651|C1274040|C3887511|C0745031|C0392348|C0205177|C0018524|C0011253|C1522326|C0031831|C0871010|G0000000|G0000000|C0681850|G0000000|C0557651|C0521115|C0033080|C0013231|C0013227|C1521739|C0242295|G0000000|C0023870|C0001721|G0000000|C0031809|C0229992|C0449438
"Prospective participants were recruited between September 2007 and June 2011 through referrals to the three study sites (Boston University [BU], Massachusetts General Hospital [MGH], and Southern Methodist University [SMU]), from other area clinical facilities and programs, and from advertisements.","Prospective participants recruited September 2007 June 2011 referrals study sites (Boston University [BU], Massachusetts General Hospital [MGH], Southern Methodist University [SMU]), clinical facilities programs, advertisements.",C0023981|C0679646|G0000000|C3828193|G0000000|C3829443|G0000000|C0034927|C0557651|C0205145|C0006037|C0041740|C0006368|C0024874|C0205246|C0019994|G0000000|C1710133|C0337739|C0041740|G0000000|C0205210|C1547538|C0376691|C0949214
Children >7 to <12 years with HIV infection could enroll if their baseline CD4% was ≥15.,Children >7 <12 HIV infection enroll baseline CD4% ≥15.,C0008059|G0000000|C0450371|C0019682|C0009450|G0000000|C0168634|C0285590|G0000000
"Participation in another trial interfering with the outcome of this study, language problems, lack of compliance, mental inability, synchronous or previous malignant disease (except curatively treated in situ cervical cancer or curatively resected non-melanoma skin cancer), systemic administration of corticosteroids, unstable angina or myocadial infarction witin 6 months of the trial, severe respiratory disease, American Society of Anesthesiologists score >3, previous major abdominal surgery, previous chemo- or radiotherapy, inadequate liver-, kidney- and bone-marrow functions and Eastern Cooperative Oncology Group status >1 are considered exclusion criteria.","Participation trial interfering outcome study, language problems, lack compliance, mental inability, synchronous previous malignant disease (except curatively treated situ cervical cancer curatively resected non-melanoma skin cancer), systemic administration corticosteroids, unstable angina myocadial infarction witin 6 months trial, severe respiratory disease, American Society Anesthesiologists score >3, previous major abdominal surgery, previous chemo- radiotherapy, inadequate liver-, kidney- bone-marrow functions Eastern Cooperative Oncology Group status >1 considered exclusion criteria.",C0679823|C0008976|C0521102|C1274040|C0557651|C0023008|C1546466|C0332268|C0009563|C0229992|G0000000|C0439580|C0205156|C0205282|C0012634|G0000000|G0000000|C1522326|G0000000|C0027530|C0006826|G0000000|C0015252|C1518422|C0444099|C0006826|C0205373|C0001554|C0001617|C0443343|C0002962|G0000000|C0021308|G0000000|G0000000|C0439231|C0008976|C0205082|C0521346|C0012634|C0596070|C0037455|C0334910|C0449820|G0000000|C0205156|C0205082|C0000726|C0038894|C0205156|C0392920|C0034619|C0205412|C0023884|C0022646|C0005953|C0542341|C1707877|C0679729|C0027651|C0441833|C0449438|G0000000|C0750591|C0680251|C0243161
"Ineligible families were determined as such because the target child had left a participating school (30%) or was not of Mexican descent (26%), or the child and caregiver were not both proficient in the same language (16%).","Ineligible families determined target child left participating school (30%) Mexican descent (26%), child caregiver proficient language (16%).",C1512714|C0015576|G0000000|C1521840|C0008059|C0205091|C0679823|C0036375|C0450371|C0240339|C0205386|C0450371|C0008059|C0085537|G0000000|C0023008|C0450371
"In brief, from June 1991 through December 1995 we enrolled 6350 healthy infants who were 2 to 61 days of age at the following eight sites: Children’s Hospital of Pittsburgh, Mercy Hospital of Pittsburgh, and two small-town and rural and four suburban private pediatric group practices in the Pittsburgh area.","In brief, June 1991 December 1995 enrolled 6350 healthy infants 2 61 days age sites: Children’s Hospital Pittsburgh, Mercy Hospital Pittsburgh, small-town rural suburban private pediatric practices Pittsburgh area.",G0000000|C1282927|C3829443|G0000000|C3830550|G0000000|G0000000|G0000000|C3898900|C0021270|G0000000|C0450371|C0439228|C0001779|C0205145|G0000000|C0019994|G0000000|G0000000|C0019994|G0000000|C0700321|C0240919|C0178856|C0033175|C0030755|C0237607|G0000000|C0017446
"The standard-fluid (Stay·Safe; 1.5%, 2.3%, and 4.25% glucose) group consisted of 20 patients (11 women, 9 men; mean age: 59 ± 15 years; 15% with diabetes); the BicaVera (1.5%, 2.3%, and 4.25% glucose) group consisted of 11 patients (3 women, 8 men; mean age: 68.22 ± 8.80; 38% with diabetes).","The standard-fluid (Stay·Safe; 1.5%, 2.3%, 4.25% glucose) consisted 20 patients (11 women, 9 men; age: 59 ± 15 years; 15% diabetes); BicaVera (1.5%, 2.3%, 4.25% glucose) consisted 11 patients (3 women, 8 men; age: 68.22 ± 8.80; 38% diabetes).",G0000000|C1442989|G0000000|G0000000|G0000000|C0450371|C0017725|C0332529|C0450371|C0030705|C0450371|C0043210|G0000000|C0025266|C0001779|C0450371|G0000000|C0450371|C0439234|C0450371|C0011847|G0000000|G0000000|G0000000|C0450371|C0017725|C0332529|C0450371|C0030705|G0000000|C0043210|G0000000|C0025266|C0001779|C0450371|G0000000|C0450371|C0450371|C0011847
"Other eligibility criteria included Eastern Cooperative Oncology Group performance status of 0 or 1, measurable disease or nonmeasurable but evaluable disease, adequate organ function, and no previous treatment for metastatic disease.","Other eligibility criteria included Eastern Cooperative Oncology Group performance status 0 1, measurable disease nonmeasurable evaluable disease, adequate organ function, previous treatment metastatic disease.",G0000000|C0013893|C0243161|C0332257|C1707877|C0679729|C0027651|C0441833|C0597198|C0449438|G0000000|G0000000|C1513040|C0012634|C1518373|C1516986|C0012634|C0205410|C0178784|C0031843|C0205156|C0039798|C0036525|C0012634
"Exclusion criteria were: (1) history of CNS disease; (2) history of CNS radiation, intrathecal therapy or CNS-involved surgery; (3) neuro-behavioral risk factors such as traumatic brain injury, history of neurological disorder, learning disability or substance addiction; (4) current psychiatric disorder.","Exclusion criteria were: (1) history CNS disease; (2) history CNS radiation, intrathecal therapy CNS-involved surgery; (3) neuro-behavioral risk factors traumatic brain injury, history neurological disorder, learning disability substance addiction; (4) current psychiatric disorder.",C0680251|C0243161|G0000000|G0000000|C0019664|C3714787|C0012634|G0000000|C0019664|C3714787|C0034519|C1370196|C0039798|C3714787|C0038894|G0000000|C2986478|C0035647|C1521761|C0332663|C0006104|C3263722|C0019664|C0205494|C0012634|C0013621|C0231170|C0439861|C0085281|G0000000|C0521116|C0205487|C0012634
"In March-April 2012, we recruited Hopi mothers or female guardians with daughters aged 9–12 years for a cluster-randomized intervention study on the Hopi Reservation.","In March-April 2012, recruited Hopi mothers female guardians daughters aged 9–12 cluster-randomized intervention study Hopi Reservation.",G0000000|C3829202|G0000000|G0000000|C0574606|C0026591|C0015780|C1274041|C0011011|C0001779|G0000000|C1555715|C0886296|C0557651|C0574606|C1514889
"Eligible women also had to report persistent fatigue starting on or after their cancer diagnosis and score ≥4 on the brief fatigue inventory (BFI) and have a low fruit and vegetable intake of less than 5.5 servings per day, not including potatoes and iceberg lettuce.","Eligible women report persistent fatigue starting cancer diagnosis score ≥4 fatigue inventory (BFI) low fruit vegetable intake 5.5 servings day, including potatoes iceberg lettuce.",C1548635|C0043210|C0684224|C0205322|C0015672|C0439659|C0006826|C0011900|C0449820|G0000000|C0015672|C0021941|C2698562|C0205251|C0016767|C0042440|C1512806|G0000000|C1519269|C0332173|C0332257|C0032846|C1449602|C0242765
Pregnant women aged 18 y or older in gestational weeks 24 through 30 who could communicate in Japanese were recruited at antenatal classes by a midwife or obstetrician or at their prenatal checkups at the sites.,Pregnant women aged 18 gestational weeks 24 30 communicate Japanese recruited antenatal classes midwife obstetrician prenatal checkups sites.,C0549206|C0043210|C0001779|C0450371|C0439671|C0439230|C0450371|C0450371|C0566001|C1556094|G0000000|C2828394|C0456387|C0026083|C0334897|C0678804|C0598836|C0205145
"[25] In our study, the cohort sample were patients with stage II and III breast cancer receiving adjuvant therapy and our results support benefits of yoga in modulating distressful symptoms related to adjuvant radiotherapy.","[25] In study, cohort sample patients stage II III breast cancer receiving adjuvant therapy support benefits yoga modulating distressful symptoms adjuvant radiotherapy.",C0450371|G0000000|C0557651|C0599755|C0370003|C0030705|C0205390|G0000000|C0439070|C0006141|C0006826|C1514756|C0001551|C0039798|C0183683|C0814225|C0043418|C0443264|C0231304|C0683368|C0001551|C0034619
"Notable exclusion criteria were as follows: pregnancy or lactation, prior chemotherapy, or bilateral oophorectomy or ovarian irradiation before enrollment; history of other cancers; personal or familial (first-degree relative) premature ovarian failure; and plan to undergo an oophorectomy/hysterectomy within 2 years.","Notable exclusion criteria follows: pregnancy lactation, prior chemotherapy, bilateral oophorectomy ovarian irradiation enrollment; history cancers; personal familial (first-degree relative) premature ovarian failure; plan undergo oophorectomy/hysterectomy 2 years.",G0000000|C0680251|C0243161|C0332283|C0032961|C0006147|C0332152|C0013216|C0238767|C0029936|C0205065|C1282930|C1516879|C0019664|C0006826|C1519021|C0015576|C0444502|C0080103|C0151526|C0205065|C0231174|C0270724|G0000000|C0029936|G0000000|C0439234
A population-based cohort consisting of all women registered in the Medical Birth Registry of Norway as having given birth between 1 January 1984 and 31 December 2010 was assembled (n = 812 986).,A population-based cohort consisting women registered Medical Birth Registry Norway birth 1 January 1984 31 December 2010 assembled (n = 812 986).,G0000000|C0032659|C0599755|C0332529|C0043210|C1514821|C0199168|C0005615|C0034975|C0028423|C0005615|G0000000|C3829466|G0000000|C0450371|C3830550|G0000000|C1706853|C0369718|G0000000|C1442061|C1442061
"Inclusion criteria for randomization were expected survival >6 months, informed consent, anastomosis ≤7 cm above the anal verge, negative air leakage test, intact anastomotic rings, and absence of major intraoperative adverse events.","Inclusion criteria randomization expected survival >6 months, informed consent, anastomosis ≤7 cm anal verge, negative air leakage test, intact anastomotic rings, absence major intraoperative adverse events.",C0007637|C0243161|C0034656|C1517001|C0038952|G0000000|C0439231|C1522154|C1511481|C0332853|G0000000|G0000000|C0003461|C0205284|C0205160|C0001861|C0015376|C0022885|C0205266|C0332854|C1260969|C0332197|C0205082|C0456904|G0000000|C0441471
"Eligibility criteria included, aged 18 years or older, histologically confirmed oesophageal SCC, sufficient performance status and fitness to undergo surgery or definitive chemoradiotherapy, tumour staged between T2N0M0 and T4N1M0 (where the T4 tumour involved the diaphragmatic crura or mediastinal pleura only), and a total primary tumour and node length of <10 cm (Sobin and Wittekind, 2002).","Eligibility criteria included, aged 18 older, histologically confirmed oesophageal SCC, sufficient performance status fitness undergo surgery definitive chemoradiotherapy, tumour staged T2N0M0 T4N1M0 (where T4 tumour involved diaphragmatic crura mediastinal pleura only), total primary tumour node length <10 cm (Sobin Wittekind, 2002).",C0013893|C0243161|C0332257|C0001779|C0450371|C0580836|C0205462|C0521093|C1522619|G0000000|C0205410|C0597198|C0449438|C1456706|G0000000|C0038894|C0443196|C0436307|C0027651|C3846398|G0000000|G0000000|G0000000|C0041403|C0027651|C1314939|C0011980|C1140621|C0025066|C0032225|C0205171|C0439175|C0205225|C0027651|C0746922|C1444754|G0000000|G0000000|G0000000|G0000000
"A total of 679 households across these villages, each of which included either a pregnant woman or child under 24 months of age, were enrolled in the study.","A total 679 households villages, included pregnant woman child 24 months age, enrolled study.",G0000000|C0439175|C1442061|C0020052|C0562518|C0332257|C0549206|C0043210|C0008059|C0450371|C0439231|C0001779|G0000000|C0557651
"For the original study, eligible survivors were required to (1) have a confirmed diagnosis of cancer; (2) have undergone and completed standard treatment for cancer; (3) have sleep disturbance (indicated by a response of 3 or greater on a clinical symptom inventory using an 11-point scale anchored by “0” = no sleep disturbance and “10” = worst possible sleep disturbance); (4) be able to read English; (5) be 21 years of age or older; (6) be able to give written informed consent; (7) not have maintained a regular personal practice of yoga within the 3 months prior to enrolling in the study or be planning to start yoga on their own during the time they are enrolled in the study; (8) not have a confirmed diagnosis of sleep apnea; (9) not be receiving any form of treatment for cancer, with the exception of hormonal or monoclonal antibody therapy; and (10) not have metastatic cancer.","For original study, eligible survivors required (1) confirmed diagnosis cancer; (2) undergone completed standard treatment cancer; (3) sleep disturbance (indicated response 3 clinical symptom inventory 11-point scale anchored “0” = sleep disturbance “10” = worst sleep disturbance); (4) read English; (5) 21 age older; (6) written informed consent; (7) maintained regular personal practice yoga 3 months prior enrolling study planning start yoga time enrolled study; (8) confirmed diagnosis sleep apnea; (9) receiving form treatment cancer, exception hormonal monoclonal antibody therapy; (10) metastatic cancer.",G0000000|C0205313|C0557651|C1548635|C0206194|C1514873|G0000000|C0521093|C0011900|C0006826|G0000000|G0000000|C0205197|C1442989|C0039798|C0006826|G0000000|C0037313|C2699787|C1444656|C0871261|G0000000|C0205210|C1457887|C0021941|C0450371|C0175659|C1293132|G0000000|G0000000|C0037313|C2699787|G0000000|G0000000|C1522166|C0037313|C2699787|G0000000|C0034754|C0376245|G0000000|C0450371|C0001779|C0580836|G0000000|C0043266|C1522154|C1511481|G0000000|C1314677|C0205272|C1519021|C0237607|C0043418|G0000000|C0439231|C0332152|G0000000|C0557651|C0032074|C0439659|C0043418|C0040223|G0000000|C0557651|G0000000|C0521093|C0011900|C0037313|C0003578|G0000000|C1514756|C0348078|C0039798|C0006826|C1554961|C0458083|C0746619|C0003241|C0039798|C0450371|C0036525|C0006826
"After the classification, 53 children with moderate deformities were recruited.","After classification, 53 children moderate deformities recruited.",G0000000|C0008902|C0450371|C0008059|C0205081|C0000768|G0000000
"In addition, women with a mammography finding requiring surgery could also be included.","In addition, women mammography finding requiring surgery included.",G0000000|C0332287|C0043210|C0024671|C0037088|G0000000|C0038894|C0332257
"Participants were 77,446 men and women, ages 50–76 years, who were residents of western Washington State and completed a baseline questionnaire between 2000 and 2002.","Participants 77,446 women, ages 50–76 years, residents western Washington State completed baseline questionnaire 2000 2002.",C0679646|C0450371|C0043210|C0001779|G0000000|C0439234|C1320928|C1705493|C0043038|C1301808|C0205197|C0168634|C0034394|G0000000|G0000000
Eighty-five recently diagnosed women with stage II and III breast cancer from two different urban cancer centers were recruited for this study over a 2-year period from January 2004 to June 2006.,Eighty-five diagnosed women stage II III breast cancer urban cancer centers recruited study 2-year period January 2004 June 2006.,C3816958|C0011900|C0043210|C0205390|G0000000|C0439070|C0006141|C0006826|C0442529|C0006826|C0205099|G0000000|C0557651|C0439234|C0439531|C3829466|G0000000|C3829443|G0000000
"Exclusion criteria included a myocardial infarction or stroke in the previous 6 months, diabetes, current yoga practice, pregnancy or plans to become pregnant, and other factors that might lead to poor retention and yoga practice, which included plans to leave the study area during the follow-up period or any contraindications to practicing yoga.","Exclusion criteria included myocardial infarction stroke previous 6 months, diabetes, current yoga practice, pregnancy plans pregnant, factors lead poor retention yoga practice, included plans leave study follow-up period contraindications practicing yoga.",C0680251|C0243161|C0332257|C0027061|C0021308|C0038454|C0205156|G0000000|C0439231|C0011847|C0521116|C0043418|C0237607|C0032961|C0270724|C0549206|C1521761|C0023175|C0032854|C0035280|C0043418|C0237607|C0332257|C0270724|G0000000|C0557651|C0589120|C0439531|C0079164|C0237607|C0043418
"Eligible patients had pathologically confirmed adenocarcinoma of the prostate, with ≥ T3 disease or < T3 with Gleason’s score (GS) > 8, or < T3 with GS 7 and PSA ≥ 15, or < T3 with GS < 7 and PSA ≥ 20, any N stage, and a negative bone scan; Zubrod performance status 0–1; age ≥ 18 years; and normal calcium levels.","Eligible patients pathologically confirmed adenocarcinoma prostate, ≥ T3 disease < T3 Gleason’s score (GS) > 8, < T3 GS 7 PSA ≥ 15, < T3 GS < 7 PSA ≥ 20, N stage, negative bone scan; Zubrod performance status 0–1; age ≥ 18 years; normal calcium levels.",C1548635|C0030705|G0000000|C0521093|C0001418|C0033572|G0000000|C0041403|C0012634|G0000000|C0041403|G0000000|C0449820|G0000000|G0000000|G0000000|G0000000|C0041403|G0000000|G0000000|C3810537|G0000000|C0450371|G0000000|C0041403|G0000000|G0000000|G0000000|C3810537|G0000000|C0450371|C0369718|C0205390|C0205160|C0262950|C0034606|C3714786|C0597198|C0449438|G0000000|C0001779|G0000000|C0450371|C0439234|C0205307|C0006675|C0441889
"Women were excluded from the study if they had (i) a documented diagnosis of a formal thought disorder (e.g., schizophrenia); (ii) any neurological injury; (iii) a Mini-Mental State Examination [62] score of ≤23; (iv) metastatic or recurrent cancer; and/or (v) those who reported prior regular meditation practice (self-defined) within the past year.","Women excluded study (i) documented diagnosis formal disorder (e.g., schizophrenia); (ii) neurological injury; (iii) Mini-Mental State Examination [62] score ≤23; (iv) metastatic recurrent cancer; and/or (v) reported prior regular meditation practice (self-defined) year.",C0043210|C1554077|C0557651|C0021966|C1301725|C0011900|C0348078|C0012634|G0000000|C0036341|G0000000|C0205494|C3263722|C0439070|C0445542|C1301808|G0000000|C0450371|C0449820|G0000000|C0022326|C0036525|C2945760|C0006826|G0000000|G0000000|C0684224|C0332152|C0205272|C0150277|C0237607|C0036588|C0439234
"The inclusion criteria were age between 4 to 14 years and a total of at least 5 eggs or larvae of any of the three intestinal helminths, namely, Ascaris lumbricoides, Trichuris trichiura, and hookworm.","The inclusion criteria age 4 14 total 5 eggs larvae intestinal helminths, namely, Ascaris lumbricoides, Trichuris trichiura, hookworm.",G0000000|C0007637|C0243161|C0001779|G0000000|C0450371|C0439175|G0000000|C0013710|C0023047|C0021853|C0018893|G0000000|C0003954|G0000000|C0040955|C3129718|C0002830
"Eligible patients were 18 years of age or older, had histological confirmation of advanced or metastatic renal cell carcinoma with a clear-cell component, measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1),16 and previous treatment with one or two antiangiogenic therapies.","Eligible patients 18 age older, histological confirmation advanced metastatic renal cell carcinoma clear-cell component, measurable disease Response Evaluation Criteria Solid Tumors (RECIST v1.1),16 previous treatment antiangiogenic therapies.",C1548635|C0030705|C0450371|C0001779|C0580836|C0205462|C0521091|C0205179|C0036525|C0022646|C0007634|C0007097|C0229473|C0449432|C1513040|C0012634|C0871261|C0220825|C0243161|C0205208|C0027651|C1709926|C0078433|C0205156|C0039798|C0596087|C0087111
A total of 371 NPC cases and 321 unaffected controls were included in the analyses.,A total 371 NPC 321 unaffected controls included analyses.,G0000000|C0439175|C1442061|G0000000|C1442061|C2986417|C0243148|C0332257|C0002778
"Inclusion criteria for this study included: (i) a diagnosis, based on conventional criteria, of Grade I or II chondrosarcoma; (ii) available follow‐up data; and (iii) all treatment done in our hospital.","Inclusion criteria study included: (i) diagnosis, based conventional criteria, Grade I II chondrosarcoma; (ii) follow‐up data; (iii) treatment hospital.",C0007637|C0243161|C0557651|C0332257|C0021966|C0011900|C1527178|C0439858|C0243161|C0441800|C0021966|G0000000|C0008479|G0000000|G0000000|C1511726|C0439070|C0039798|C0019994
"Male and female patients, aged 18–65 years, who sustained an ankle sprain <48 hours before study entry and had a pain score ≥50 mm on a 100 mm visual analog scale were included in this study if the injury justified use of a seven-day NSAID topical treatment.","Male female patients, aged 18–65 years, sustained ankle sprain <48 hours study entry pain score ≥50 mm 100 mm visual analog scale included study injury justified seven-day NSAID topical treatment.",C0086582|C0015780|C0030705|C0001779|G0000000|C0439234|C0443318|C0003086|C0038045|C0450371|C0439227|C0557651|C1705654|C0030193|C0449820|G0000000|G0000000|C1442061|G0000000|C0234621|C0243071|C0175659|C0332257|C0557651|C3263722|C1552821|C1710063|C0003211|C0332237|C0039798
"A total of 333 patients were randomised and treated (IF 170, CF 163).","A total 333 patients randomised treated (IF 170, CF 163).",G0000000|C0439175|C1442061|C0030705|G0000000|C1522326|G0000000|C1442061|C0009738|C1442061
"Between 1997 and 1999 patients with a histological diagnosis of diffuse mixed cell, diffuse large cell or diffuse immunoblastic lymphoma according to the Working Formulation were included.","Between 1997 1999 patients histological diagnosis diffuse mixed cell, diffuse cell diffuse immunoblastic lymphoma Working Formulation included.",G0000000|G0000000|G0000000|C0030705|C0205462|C0011900|C0205219|C0205430|C0007634|C0205219|C0007634|C0205219|C1512654|C0024299|C0043227|C0524527|C0332257
"Patients 13 years or older in whom the CAI was maintained at 5 or less while receiving drugs such as mesalazine, salazosulfapyridine, or steroids, with no change in treatment regimens within 4 wk before study entry, were enrolled in this randomized, double-blind, placebo-controlled study.","Patients 13 CAI maintained 5 receiving drugs mesalazine, salazosulfapyridine, steroids, change treatment regimens 4 wk study entry, enrolled randomized, double-blind, placebo-controlled study.",C0030705|C0450371|C0064494|C1314677|G0000000|C1514756|C0013227|C0127615|C0036078|C0038317|C0392747|C0039798|C2945654|G0000000|C0332174|C0557651|C1705654|G0000000|C0034656|C0013072|C1706408|C0557651
"Exclusion criteria included the following: significant cardiac disease, renal failure, significant symptomatic lymphedema, and physical or psychological comorbidities that would prohibit exercise testing or participation, diagnosis of diabetes mellitus, or active smoking status.","Exclusion criteria included following: cardiac disease, renal failure, symptomatic lymphedema, physical psychological comorbidities prohibit exercise testing participation, diagnosis diabetes mellitus, active smoking status.",C0680251|C0243161|C0332257|C0231290|C0018787|C0012634|C0022646|C0231174|C0231220|C0024236|C0031809|C0205486|C0009488|C0138547|C0015259|C0039593|C0679823|C0011900|C0011847|G0000000|C0205177|C0037369|C0449438
Exclusion criteria were: women under 17 years old; infants diagnosed with a serious medical condition or on special diets; infants aged over 12 weeks; women or their partners from social class I.,Exclusion criteria were: women 17 old; infants diagnosed medical condition special diets; infants aged 12 weeks; women partners social class I.,C0680251|C0243161|G0000000|C0043210|C0450371|C0580836|C0021270|C0011900|C0199168|C0012634|C0205555|C0012155|C0021270|C0001779|C0450371|C0439230|C0043210|C0682323|C0728831|C0456387|C0021966
"Patients were more than 18 years of age, with histologically confirmed, inoperable, locally advanced or recurrent, and/or metastatic adenocarcinoma of the stomach or gastroesophageal junction.","Patients 18 age, histologically confirmed, inoperable, locally advanced recurrent, and/or metastatic adenocarcinoma stomach gastroesophageal junction.",C0030705|C0450371|C0001779|C0205462|C0521093|C0205187|C1517927|C0205179|C2945760|G0000000|C0036525|C0001418|C0038351|C0744316|C0205144
Only untreated patients were eligible.,Only untreated patients eligible.,C0205171|C0332155|C0030705|C1548635
"Sixty-three post-treatment stage 0–III borderline overweight and obese (body mass index ≥ 24 kg/m2) breast cancer survivors were randomly assigned to a 6-month, facility- and home-based viniyoga intervention (n = 32) or a waitlist control group (n = 31).","Sixty-three post-treatment stage 0–III borderline overweight obese (body mass ≥ 24 kg/m2) breast cancer survivors randomly assigned 6-month, facility- home-based viniyoga intervention (n = 32) waitlist control (n = 31).",C3816724|C2709088|C0205390|G0000000|C0205189|C0497406|C0028754|C0242821|C0577559|G0000000|C0450371|C0022718|C0006141|C0006826|C0206194|G0000000|C1516050|C0332177|C1547538|C0442519|G0000000|C0886296|C0369718|G0000000|C0450371|C0043010|C0243148|C0369718|G0000000|C0450371
"Participants included 185 children, age 8–17 years, with a diagnosis of Crohn's or Ulcerative Colitis (UC) at least three months post-diagnosis, and their parents.","Participants included 185 children, age 8–17 years, diagnosis Crohn's Ulcerative Colitis (UC) months post-diagnosis, parents.",C0679646|C0332257|C1442061|C0008059|C0001779|G0000000|C0439234|C0011900|C0010346|C0041582|C0009319|G0000000|C0439231|C0687676|C0030551
"After exclusion of those with missing responses or with a prior history of cancer, 14 409 subjects in Cohort 1 and 20 595 in Cohort 2 remained.","After exclusion missing responses prior history cancer, 14 409 subjects Cohort 1 20 595 Cohort 2 remained.",G0000000|C0680251|C1551393|C0871261|C0332152|C0019664|C0006826|G0000000|C0681850|C0599755|G0000000|G0000000|C0599755|G0000000|G0000000
Patients who were allergic to macrolides and patients with impaired hepatic disease or diabetes mellitus had also been excluded.,Patients allergic macrolides patients impaired hepatic disease diabetes mellitus excluded.,C0030705|C0700624|C0003240|C0030705|C0221099|C0205054|C0012634|C0011847|G0000000|C1554077
"Participants were also required to meet the following criteria: not taking either tamoxifen or raloxifene, hormone therapy, oral contraceptives, or androgens for at least 3 months before randomization; not currently taking warfarin or cholestyramine; no history of stroke, transient ischemic attack, pulmonary embolism, or deep-vein thrombosis; no atrial fibrillation, uncontrolled diabetes, or uncontrolled hypertension; no psychiatric condition that would interfere with adherence; a performance status that would not restrict normal activity; and no history of previous malignancy except basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or LCIS of the breast.","Participants required meet criteria: tamoxifen raloxifene, hormone therapy, oral contraceptives, androgens 3 months randomization; warfarin cholestyramine; history stroke, transient ischemic attack, pulmonary embolism, deep-vein thrombosis; atrial fibrillation, uncontrolled diabetes, uncontrolled hypertension; psychiatric condition interfere adherence; performance status restrict normal activity; history previous malignancy basal cell squamous cell carcinoma skin, carcinoma situ cervix, LCIS breast.",C0679646|C1514873|C1550543|C0243161|C0039286|C0244404|C0019932|C0039798|C0442027|C0009871|C0002844|G0000000|C0439231|C0034656|C0043031|C0008402|C0019664|C0038454|C0040704|C0475224|C0277793|C0024109|C0013922|C0226514|C0040053|C0018792|C0232197|C0205318|C0011847|C0205318|C0020538|C0205487|C0012634|C0521102|C1510802|C0597198|C0449438|C0443288|C0205307|C0205177|C0019664|C0205156|C0006826|C0205112|C0007634|C1182670|C0007634|C0007097|C0444099|C0007097|G0000000|C0007874|C0279563|C0006141
"Exclusion criteria were pregnancy, symptoms suggestive of severe disease and prior study inclusion within the previous 28 days.","Exclusion criteria pregnancy, symptoms suggestive severe disease prior study inclusion previous 28 days.",C0680251|C0243161|C0032961|C0683368|C0332299|C0205082|C0012634|C0332152|C0557651|C0007637|C0205156|C0450371|C0439228
Cases with symptoms of bowel obstruction which were temporary and restorable with short medical treatment were excluded.,Cases symptoms bowel obstruction temporary restorable short medical treatment excluded.,C0868928|C0683368|C0021853|C0028778|C0205374|G0000000|C1282927|C0199168|C0039798|C1554077
A total of 23 late stage cancer patients were recruited and were divided into two dose/volume cohorts in a three immunization protocol.,A total 23 late stage cancer patients recruited divided dose/volume cohorts immunization protocol.,G0000000|C0439175|C0450371|C0205087|C0205390|C0006826|C0030705|G0000000|C0332849|C0178602|C0599755|C0020971|C0442711
"A random sample of 650 were selected, 209 of whom were excluded because they had had a hysterectomy, had had a recent Pap test, had moved or had records containing clerical errors.","A random sample 650 selected, 209 excluded hysterectomy, Pap test, moved records clerical errors.",G0000000|C0034656|C0370003|C1442061|C1707391|C1442061|C1554077|C0020699|C1740167|C0022885|C1269909|C0034869|C0008935|C0743559
"Exclusion criteria included neuroendocrine histology, pathologically proven distant metastasis, history of psychiatric disease, preoperative urinary dysfunction, and another coexisting malignancy.","Exclusion criteria included neuroendocrine histology, pathologically proven distant metastasis, history psychiatric disease, preoperative urinary dysfunction, coexisting malignancy.",C0680251|C0243161|C0332257|C0027912|C0019638|G0000000|C0456369|C0443203|C0027627|C0019664|C0205487|C0012634|C0445204|C0042027|C0031847|G0000000|C0006826
"Additional exclusion criteria included patients with advanced CLI (Rutherford Category 6), expected amputation within 4 weeks of screening, clinical evidence of sepsis, advanced AV block or NYHA Class III or Class IV heart failure, myocardial infarction within 3 months, or clinically successful aortic or lower extremity arterial surgery, percutaneous revascularization, or lumbar sympathectomy within 3 months preceding screening.","Additional exclusion criteria included patients advanced CLI (Rutherford Category 6), expected amputation 4 weeks screening, clinical evidence sepsis, advanced AV block NYHA Class III Class IV heart failure, myocardial infarction 3 months, clinically successful aortic lower extremity arterial surgery, percutaneous revascularization, lumbar sympathectomy 3 months preceding screening.",C1524062|C0680251|C0243161|C0332257|C0030705|C0205179|G0000000|G0000000|C0683312|G0000000|C1517001|C0002688|G0000000|C0439230|C0220908|C0205210|C3887511|C0036690|C0205179|G0000000|C0028778|G0000000|C0456387|C0439070|C0456387|C0022326|C0018787|C0231174|C0027061|C0021308|G0000000|C0439231|G0000000|C0597535|C0003483|C0441994|C0015385|C0003842|C0038894|C0522523|C0581603|C0024090|C0039038|G0000000|C0439231|C0332152|C0220908
Women were excluded if they had a serious infection or reported previous use of antiretroviral drugs during this or previous pregnancies.,Women excluded infection reported previous antiretroviral drugs previous pregnancies.,C0043210|C1554077|C0009450|C0684224|C0205156|G0000000|C0013227|C0205156|C0032961
Patients (male or female) ≥18 years were eligible for the study if they had metabolic syndrome as defined by the presence of at least three of the following: Abdominal obesity (waist circumference >102 cm for men and >88 cm for women); TG ≥1.70 mmol/L (150 mg/dL); HDL-C <1.04 mmol/L (40 mg/dL) for men and <1.30 mmol/L (50 mg/dL) for women; Blood Pressure ≥130/85 mmHg or receiving antihypertensive treatment; and Fasting blood glucose ≥6.11 mmol/L (110 mg/dL).,Patients (male female) ≥18 eligible study metabolic syndrome defined presence following: Abdominal obesity (waist circumference >102 cm >88 cm women); TG ≥1.70 mmol/L (150 mg/dL); HDL-C <1.04 mmol/L (40 mg/dL) <1.30 mmol/L (50 mg/dL) women; Blood Pressure ≥130/85 mmHg receiving antihypertensive treatment; Fasting blood glucose ≥6.11 mmol/L (110 mg/dL).,C0030705|C0086582|C0015780|G0000000|C1548635|C0557651|C0311400|C0039082|C1704788|C0150312|C0231290|C0000726|C0028754|C0230097|C0332520|C1442061|G0000000|C0450371|G0000000|C0043210|C0337445|G0000000|C1532563|C1442061|C0439269|C3715113|C0450371|C1532563|C0450371|C0439269|C0450371|C1532563|C0450371|C0439269|C0043210|C0005767|C0033095|G0000000|C0439475|C1514756|C0003364|C0039798|C0015663|C0005767|C0017725|G0000000|C1532563|C1442061|C0439269
The median age of patients was 62 years and the median KPS was 90%.,The median age patients 62 median KPS 90%.,G0000000|C0549183|C0001779|C0030705|C0450371|C0549183|C0206065|C0450371
Follow-up children will be excluded if they meet the following criteria: 1) Their parents are principal investigators or study personnel of the trial.,Follow-up children excluded meet criteria: 1) Their parents principal investigators study personnel trial.,C0589120|C0008059|C1554077|C1550543|C0243161|G0000000|G0000000|C0030551|C0205225|C0035173|C0557651|C0024752|C0008976
"Exclusion criteria included, ‘children with developmental problems, cerebral palsy, Down syndrome, inborn errors of metabolism, a history of epileptic fits, body weight less than 10 kg, or greater than 26 kg (Children below age of six years with body weight more than 26 kg were definitely obese with a risk of airway obstruction, along with the abnormal volume of distribution of drugs if given according to their actual body weight).","Exclusion criteria included, ‘children developmental problems, cerebral palsy, Down syndrome, inborn errors metabolism, history epileptic fits, body weight 10 kg, 26 (Children age body weight 26 obese risk airway obstruction, abnormal volume distribution drugs actual body weight).",C0680251|C0243161|C0332257|G0000000|C0458003|C1546466|G0000000|C0522224|G0000000|C0039082|G0000000|C0743559|C0025519|C0019664|C0014544|C0036572|C0242821|C0005910|C0450371|C0022718|C0450371|C0008059|C0001779|C0242821|C0005910|C0450371|C0028754|C0035647|C0178987|C0028778|C0205161|C0449468|C0520511|C0013227|C0237400|C0242821|C0005910
"Therefore, a randomized, placebo-controlled trial (RCT) and an open-label extension (OLE) study were conducted to determine the efficacy and safety of fixed-dose subcutaneous MNTX in patients with advanced illness and OIC in a variety of health care situations.","Therefore, randomized, placebo-controlled trial (RCT) open-label extension (OLE) study conducted determine efficacy safety fixed-dose subcutaneous MNTX patients advanced illness OIC variety health care situations.",G0000000|C0034656|C1706408|C0008976|G0000000|C1709323|C0231448|G0000000|C0557651|C0004927|G0000000|C1280519|C0036043|C0443218|C0443315|C0066411|C0030705|C0205179|C0221423|C0268358|C1883525|C0018684|C1947933|G0000000
"The primary reasons for ineligibility were cancer-related, including diagnosis with Stage 3 or 4 breast cancer (n = 23), no previous breast cancer diagnosis (n = 19), less than 6 months post treatment completion (n = 11), and other cancer in last 5 years (n = 3).","The primary reasons ineligibility cancer-related, including diagnosis Stage 3 4 breast cancer (n = 23), previous breast cancer diagnosis (n = 19), 6 months post treatment completion (n = 11), cancer 5 (n = 3).",G0000000|C0205225|C0392360|C1512714|C2826292|C0332257|C0011900|C0205390|G0000000|G0000000|C0006141|C0006826|C0369718|G0000000|C0450371|C0205156|C0006141|C0006826|C0011900|C0369718|G0000000|C0450371|G0000000|C0439231|C0687676|C0039798|C0205197|C0369718|G0000000|C0450371|C0006826|G0000000|C0369718|G0000000|G0000000
"Women were eligible for inclusion in the trial if they were 18 years of age or older, were premenopausal with follicle-stimulating hormone (FSH) level less than 10 mIU/L, had reported at least moderately severe leiomyoma-related symptoms (a score of ≥25 on the UF quality-of-life symptom severity subscale), had a total uterine volume of ≥160 mL by vaginal and abdominal ultrasound and at least one UF/leiomyoma that was ≥2 cm3.","Women eligible inclusion trial 18 age older, premenopausal follicle-stimulating hormone (FSH) level 10 mIU/L, reported moderately severe leiomyoma-related symptoms (a score ≥25 UF quality-of-life symptom severity subscale), total uterine volume ≥160 mL vaginal abdominal ultrasound UF/leiomyoma ≥2 cm3.",C0043210|C1548635|C0007637|C0008976|C0450371|C0001779|C0580836|C0279752|C0018120|C0019932|G0000000|C0441889|C0450371|C0439462|C0684224|C0205081|C0205082|C0023267|C0683368|G0000000|C0449820|G0000000|G0000000|C0332306|C1457887|C0439793|G0000000|C0439175|C0042149|C0449468|G0000000|C0439526|C0042232|C0000726|C0041618|C0023267|G0000000|G0000000
"To be eligible, participants need to: (1) have a confirmed diagnosis of colon or rectal cancer; (2) have stage I to III disease (that is, non-metastatic); (3) be treated with curative intent with surgery +/− radiation +/− chemotherapy; (4) be over 18 years; and (5) be able to understand English.","To eligible, participants to: (1) confirmed diagnosis colon rectal cancer; (2) stage I III disease (that is, non-metastatic); (3) treated curative intent surgery +/− radiation +/− chemotherapy; (4) 18 years; (5) understand English.",C0040363|C1548635|C0679646|G0000000|G0000000|C0521093|C0011900|C0009368|C0205052|C0006826|G0000000|C0205390|C0021966|C0439070|C0012634|G0000000|G0000000|C1518422|G0000000|C1522326|C1880198|C0162425|C0038894|G0000000|C0034519|G0000000|C0013216|G0000000|C0450371|C0439234|G0000000|C0162340|C0376245
Participants are underactive women aged 50–75 years who completed chemotherapy for cancers without neurologic involvement.,Participants underactive women aged 50–75 completed chemotherapy cancers neurologic involvement.,C0679646|C0391853|C0043210|C0001779|G0000000|C0205197|C0013216|C0006826|C0205494|C1314939
Smokers were excluded because investigators held it was more important to engage these women in a smoking cessation program than a weight loss program.,Smokers excluded investigators held engage women smoking cessation program weight loss program.,C0337664|C1554077|C0035173|C0675390|G0000000|C0043210|C0037369|C1880019|C1709697|C0005910|C1517945|C1709697
"Patients ≥ 18 years newly diagnosed with acute leukemia are eligible for the study upon completion of their initial induction chemotherapy with a documented complete remission (CR) status, able to read and understand Danish and can provide a signed informed written consent.","Patients ≥ 18 newly diagnosed acute leukemia eligible study completion initial induction chemotherapy documented complete remission (CR) status, read understand Danish provide signed informed written consent.",G0000000|C0750546|C0011900|C0205178|C0023418|C1548635|C0557651|C0205197|C0205265|C0205263|C0013216|C1301725|C0205197|C0544452|C0201975|C0449438|C0034754|C0162340|G0000000|C1999230|C1519316|C1522154|C0043266|C1511481
Inclusion criteria were: (1) diagnosis of stage I or II breast cancer; (2) at least 18 months post-treatment currently disease free (not excluding individuals on hormonal therapies such as selective estrogen receptor modulators or aromatase inhibitors); (3) treatment involved standard dose adjuvant chemotherapy; (4) complaint of memory and attention problems following chemotherapy; (5) able to speak and read English; (6) at least 18 years of age at diagnosis and able to provide informed written consent.,Inclusion criteria were: (1) diagnosis stage I II breast cancer; (2) 18 months post-treatment disease free (not excluding individuals hormonal therapies selective estrogen receptor modulators aromatase inhibitors); (3) treatment involved standard dose adjuvant chemotherapy; (4) complaint memory attention chemotherapy; (5) speak read English; (6) 18 age diagnosis provide informed written consent.,C0007637|C0243161|G0000000|G0000000|C0011900|C0205390|C0021966|G0000000|C0006141|C0006826|G0000000|C0450371|C0439231|C2709088|C0012634|C0332296|C1518422|C0332196|C0027361|C0458083|C0087111|C0036576|C0014939|C0597357|C1709060|C0003805|C0243077|G0000000|C0039798|C1314939|C1442989|C0178602|C0001551|C0013216|G0000000|C0277786|C0025260|C0004268|C0013216|G0000000|C0234856|C0034754|C0376245|G0000000|C0450371|C0001779|C0011900|C1999230|C1522154|C0043266|C1511481
"Eligibility criteria included women older than 18 years old who had operable breast cancer and whose treating physicians deemed they needed adjuvant chemotherapy based on their tumor size, grade, hormone receptor status, HER2/neu status, lymphovascular involvement, and potentially other factors.","Eligibility criteria included women 18 operable breast cancer treating physicians deemed adjuvant chemotherapy based tumor size, grade, hormone receptor status, HER2/neu status, lymphovascular involvement, factors.",C0013893|C0243161|C0332257|C0043210|C0450371|C0205188|C0006141|C0006826|C1522326|C0031831|G0000000|C0001551|C0013216|C1527178|C0027651|C0456389|C0441800|C0019932|C0597357|C0449438|C1702024|C0449438|C1518090|C1314939|C1521761
Forty-two patients with severe sepsis were enrolled in the study.,Forty-two patients severe sepsis enrolled study.,C3816449|C0030705|C0205082|C0036690|G0000000|C0557651
"Twenty-five patients underwent intralesional resection, 18 had wide resection, and three had amputations.","Twenty-five patients underwent intralesional resection, 18 wide resection, amputations.",C3715062|C0030705|G0000000|C1512954|C0015252|C0450371|C0332464|C0015252|C0002688
Inclusion criteria were: 1) diagnosed with Stage 0 – III breast cancer at or before age 50; and 2) completed local and/or adjuvant cancer therapy (except hormonal therapy) at least 3 months previously.,Inclusion criteria were: 1) diagnosed Stage 0 – III breast cancer age 50; 2) completed local and/or adjuvant cancer therapy (except hormonal therapy) 3 months previously.,C0007637|C0243161|G0000000|G0000000|C0011900|C0205390|G0000000|G0000000|C0439070|C0006141|C0006826|C0001779|C0450371|G0000000|C0205197|C0205276|G0000000|C0001551|C0006826|C0039798|G0000000|C0458083|C0039798|G0000000|C0439231|G0000000
"Exclusion criteria were: 1) A history of confirmed or suspected heart disease; 2) The presence of other concomitant illness; 3) Patients treated by herbal medicine, vitamins and enzymes; 4) Arrhythmia in ECG; 5) Inappropriate view in echocardiography.","Exclusion criteria were: 1) A history confirmed suspected heart disease; 2) The presence concomitant illness; 3) Patients treated herbal medicine, vitamins enzymes; 4) Arrhythmia ECG; 5) Inappropriate view echocardiography.",C0680251|C0243161|G0000000|G0000000|G0000000|C0019664|C0521093|C0332147|C0018787|C0012634|G0000000|G0000000|C0150312|C0521115|C0221423|G0000000|C0030705|C1522326|C3146288|C0013227|C0042890|C0014442|G0000000|C0003811|C1623258|G0000000|C1548788|C0449911|C0013516
"Other medical or psychiatric problems (e.g., myocardial infarction and orthopedic problems) that might interfere with protocol adherence were exclusion criteria.","Other medical psychiatric (e.g., myocardial infarction orthopedic problems) interfere protocol adherence exclusion criteria.",G0000000|C0199168|C0205487|G0000000|C0027061|C0021308|C0029355|C1546466|C0521102|C0442711|C1510802|C0680251|C0243161
"In total, 132 severely fatigued breast cancer survivors will be recruited and randomized to either an intervention condition or care as usual (ratio 1:1).","In total, 132 severely fatigued breast cancer survivors recruited randomized intervention condition care usual (ratio 1:1).",G0000000|C0439175|C1442061|C0205082|C0015672|C0006141|C0006826|C0206194|G0000000|C0034656|C0886296|C0012634|C1947933|C3538928|C0456603|G0000000
"Median age was 68 years (range, 32–86 years), 45.3% (106 of 234) were females, 79.1% (185 of 234) had preoperative radiotherapy, the level of anastomosis was median 5 cm, and intraoperative blood loss 550 mL, without differences between the groups.","Median age 68 (range, 32–86 years), 45.3% (106 234) females, 79.1% (185 234) preoperative radiotherapy, level anastomosis median 5 cm, intraoperative blood loss 550 mL, differences groups.",C0549183|C0001779|C0450371|C1514721|G0000000|C0439234|C0450371|C1442061|C1442061|C0015780|C0450371|C1442061|C1442061|C0445204|C0034619|C0441889|C0332853|C0549183|G0000000|G0000000|C0456904|C0005767|C1517945|C1442061|C0439526|C1705241|C0441833
"Eligible breast cancer patients were between 18 and 70 years of age, surgically treated for early stage breast cancer (mastectomy or lumpectomy), and allocated to adjuvant chemotherapy according to the national treatment guidelines of the Norwegian Breast Cancer Group.","Eligible breast cancer patients 18 70 age, surgically treated stage breast cancer (mastectomy lumpectomy), allocated adjuvant chemotherapy national treatment guidelines Norwegian Breast Cancer Group.",C1548635|C0006141|C0006826|C0030705|C0450371|C0450371|C0001779|C0543467|C1522326|C0205390|C0006141|C0006826|C0024881|C0851238|G0000000|C0001551|C0013216|C3245503|C0039798|C0162791|C0337812|C0006141|C0006826|C0441833
Survey respondents included women of reproductive age (15–49) with a child less than six years of age.,Survey respondents included women reproductive age (15–49) child age.,C0038951|C0282122|C0332257|C0043210|C0035150|C0001779|G0000000|C0008059|C0001779
"Overall, 200 patients met these criteria.","Overall, 200 patients met criteria.",C0282416|C1442061|C0030705|C0268621|C0243161
Exclusion criteria were participation in interfering clinical trials and expected lack of compliance.,Exclusion criteria participation interfering clinical trials expected lack compliance.,C0680251|C0243161|C0679823|C0521102|C0205210|C0008976|C1517001|C0332268|C0009563
"Four hundred and ninety patients who underwent adjuvant postoperative radiation therapy after surgery for sigmoid, rectal, or cervical cancer were assigned to either the high-potency probiotic preparation VSL#3 (one sachet t.i.d.,) or placebo starting from the first day of radiation therapy.","Four patients underwent adjuvant postoperative radiation therapy surgery sigmoid, rectal, cervical cancer assigned high-potency probiotic preparation VSL#3 (one sachet t.i.d.,) placebo starting day radiation therapy.",C0205450|C0030705|G0000000|C0001551|C0032790|C0034519|C0039798|C0038894|C0227391|C0205052|C0027530|C0006826|C1516050|C0205250|C0525033|C1521827|G0000000|C0205447|C1319685|C2603360|C0032042|C0439659|C0332173|C0034519|C0039798
"Key exclusion criteria included central nervous system metastases, previous treatment with an mTOR inhibitor, or a condition requiring glucocorticoids (>10 mg daily prednisone equivalent).","Key exclusion criteria included central nervous system metastases, previous treatment mTOR inhibitor, condition requiring glucocorticoids (>10 daily prednisone equivalent).",G0000000|C0680251|C0243161|C0332257|C0205099|C0027769|C0449913|C0027627|C0205156|C0039798|C1307407|C1999216|C0012634|G0000000|C0017710|C0450371|C0332173|C0032952|C0205163
"The mean age at presentation among the participants was 28.1 years, with a mean follow-up of 21.4 years; 89% of the participants were followed-up for at least 10 years and 14% for at least 30 years.","The age presentation participants 28.1 years, follow-up 21.4 years; 89% participants followed-up 10 14% 30 years.",G0000000|C0001779|C0449450|C0679646|C0450371|C0439234|C0589120|C0450371|C0439234|C0450371|C0679646|C0332283|C0450371|C0450371|C0450371|C0439234
Male or female patients aged 6–18 years old suffering from acute bronchitis with symptoms starting ≤48 h prior to inclusion in the study and with a total score of bronchitis-specific symptoms (BSS) ≥5 points at screening were included in the study.,Male female patients aged 6–18 suffering acute bronchitis symptoms starting ≤48 prior inclusion study total score bronchitis-specific symptoms (BSS) ≥5 screening included study.,C0086582|C0015780|C0030705|C0001779|G0000000|C0683278|C0205178|C0006277|C0683368|C0439659|G0000000|C0332152|C0007637|C0557651|C0439175|C0449820|C0006277|C0683368|G0000000|G0000000|C0220908|C0332257|C0557651
"Inclusion criteria were as follows: (i) child ages 7–17 years, (ii) three or more episodes of recurrent abdominal pain during a 3-month period, and (iii) child and parent cohabited for the past 5 years or, in cases of divided custody, for at least half of the child's lifetime.","Inclusion criteria follows: (i) child ages 7–17 years, (ii) episodes recurrent abdominal pain 3-month period, (iii) child parent cohabited 5 or, divided custody, half child's lifetime.",C0007637|C0243161|C0332283|C0021966|C0008059|C0001779|G0000000|C0439234|G0000000|C0332189|C2945760|C0000726|C0030193|C0332177|C0439531|C0439070|C0008059|C0030551|G0000000|G0000000|G0000000|C0332849|G0000000|C2825407|C0008059|C4071830
"All participants were sedentary (< 150 minutes of physical activity [PA] a week), overweight or obese (body mass index, 25 to 40 kg/m2), and over age 65 years.","All participants sedentary (< 150 minutes physical activity [PA] week), overweight obese (body mass index, 25 40 kg/m2), age 65 years.",G0000000|C0679646|C0205254|G0000000|C1442061|C0439232|C0031809|C0205177|C0030428|C0332174|C0497406|C0028754|C0242821|C0577559|C0918012|C0450371|C0450371|C0022718|C0001779|C0450371|C0439234
"Patients with a history of chronic or acute regional enteritis, malabsorption syndrome(s), or other history of inflammatory bowel disease; patients with uncontrolled diabetes and cholecystitis or gallstones (unless cholecystectomy was performed); patients with colostomy or those who had abdominoperineal resection or other surgery leaving the patient without a functioning rectum were also excluded.","Patients history chronic acute regional enteritis, malabsorption syndrome(s), history inflammatory bowel disease; patients uncontrolled diabetes cholecystitis gallstones (unless cholecystectomy performed); patients colostomy abdominoperineal resection surgery leaving patient functioning rectum excluded.",C0030705|C0019664|C0205191|C0205178|C0205147|C0014335|C0024523|C0039082|C0019664|C0333348|C0021853|C0012634|C0030705|C0205318|C0011847|C0008325|C0008350|G0000000|C0008320|C0884358|C0030705|C0009410|C0442411|C0015252|C0038894|G0000000|C0030705|C0205245|C0034896|C1554077
"We excluded patients with Ollier’s disease (nine cases), with inadequate radiographic documentation (11 cases), and with less than 60 months followup (five cases); we also excluded patients with CS of the short bones and those seen for consultation only.","We excluded patients Ollier’s disease (nine cases), inadequate radiographic documentation (11 cases), 60 months followup (five cases); excluded patients CS short bones consultation only.",G0000000|C1554077|C0030705|G0000000|C0012634|C0205455|C0868928|C0205412|C0444708|C0175636|C0450371|C0868928|C0450371|C0439231|C0589120|C0205451|C0868928|C1554077|C0030705|C0010182|C1282927|C0262950|C0009818|C0205171
"The remaining 146 patients (57 women, 89 men) were randomized in two groups: ES (n = 72) and UC (n = 74).","The remaining 146 patients (57 women, 89 men) randomized groups: ES (n = 72) UC (n = 74).",G0000000|C1527428|C1442061|C0030705|C0450371|C0043210|C0450371|C0025266|C0034656|C0441833|C0013754|C0369718|G0000000|C0450371|G0000000|C0369718|G0000000|C0450371
"We conducted this cluster-randomized interventional trial at Bhains Colony (Cattle Colony), a peri-urban setting of Karachi located in Bin Qasim Town, with a total population of 56,178 according to the 2007 census.","We conducted cluster-randomized interventional trial Bhains Colony (Cattle Colony), peri-urban setting Karachi located Bin Qasim Town, total population 56,178 2007 census.",G0000000|C0004927|C1555715|C1948041|C0008976|G0000000|C0439158|C0007452|C0439158|C0347985|C0542559|G0000000|G0000000|C1879840|G0000000|C0557750|C0439175|C0032659|C0450371|G0000000|C0007663
"This is a follow-up study of a two-armed, open cluster-randomized education intervention regarding nutrition, stimulation and hygiene among impoverished mothers of children aged 6-8 months in the Kisoro and Kabale districts of South-Western Uganda.","This follow-up study two-armed, cluster-randomized education intervention nutrition, stimulation hygiene impoverished mothers children aged 6-8 months Kisoro Kabale districts South-Western Uganda.",G0000000|C0589120|C0557651|C0205448|C1555715|C0013621|C0886296|C0028707|C1292856|C0020405|G0000000|C0026591|C0008059|C0001779|G0000000|C0439231|G0000000|G0000000|G0000000|C1710133|C0041573
"Children with acute asthma, an FEV1<50% and with treatment during the preceding 2 months with ICS, cromones, leukotriene modifiers or long-acting β2-agonists were excluded.","Children acute asthma, FEV1<50% treatment preceding 2 months ICS, cromones, leukotriene modifiers long-acting β2-agonists excluded.",C0008059|C0205178|C0004096|C0450371|C0039798|C0332152|G0000000|C0439231|C0022521|G0000000|C0023545|C0205349|C0205166|G0000000|C1554077
"Children were included if they presented with co-morbid difficulties (i.e., language difficulties, conduct disorder) and were excluded if they were diagnosed with other major developmental disorders (i.e., intellectual disability, autism spectrum disorder).","Children included co-morbid difficulties (i.e., language difficulties, conduct disorder) excluded diagnosed major developmental disorders (i.e., intellectual disability, autism spectrum disorder).",C0008059|C0332257|C0009488|C1299586|C0683454|C0023008|C1299586|C0004927|C0012634|C1554077|C0011900|C0205082|C0458003|C0012634|C0683454|G0000000|C0231170|C0004352|C1883073|C0012634
"Subjects were required to be healthy, not taking any other investigational products or immune-modifying drugs, not pregnant or planning to become pregnant, or breastfeeding during the study.","Subjects required healthy, investigational products immune-modifying drugs, pregnant planning pregnant, breastfeeding study.",C0681850|C1514873|C3898900|C1517586|C1514468|C0439662|C0013227|C0549206|C0032074|C0549206|C0006147|C0557651
We excluded 997 pregnancies with estimated date of conception less than one year from the data freeze date (including 76 (7.6%) miscarriages and 3 (0.3%) stillbirths) and 114 pregnancies with missing date of last menstrual period (among which there were 14 (12%) miscarriages and 2 (2%) stillbirths).,We excluded 997 pregnancies estimated conception data freeze (including 76 (7.6%) miscarriages 3 (0.3%) stillbirths) 114 pregnancies missing menstrual period (among 14 (12%) miscarriages 2 (2%) stillbirths).,G0000000|C1554077|C1442061|C0032961|C0750572|C0009637|C1511726|C0016701|C0332257|C0450371|G0000000|C0000786|G0000000|G0000000|C0595939|C1442061|C0032961|C1551393|C0025344|C0439531|G0000000|C0450371|C0450371|C0000786|G0000000|G0000000|C0595939
"Patients with any of the following conditions or characteristics are excluded from the study: locally advanced cancer, junctional Siewert one oesophago-gastric cancer (An amendment is being submitted to our ethic committee in order to include these cancers together with other oesophageal cancers), gastric or junctional oesophago-gastric cancer with dysphagia, gastric or junctional oesophago-gastric cancer with unknown or positive HER2 status, compression of the biliary tract without any bypass procedure.","Patients conditions characteristics excluded study: locally advanced cancer, junctional Siewert oesophago-gastric cancer (An amendment submitted ethic committee cancers oesophageal cancers), gastric junctional oesophago-gastric cancer dysphagia, gastric junctional oesophago-gastric cancer unknown positive HER2 status, compression biliary tract bypass procedure.",C0030705|C0012634|C1521970|C1554077|C0557651|C1517927|C0205179|C0006826|C0205144|G0000000|C1522619|C0006826|G0000000|C0680532|C1515023|C0015000|C2699414|C0006826|C1522619|C0006826|C0038351|C0205144|C1522619|C0006826|C0011168|C0038351|C0205144|C1522619|C0006826|C0439673|C0439178|G0000000|C0449438|C0332459|C0521378|C1185740|C0741847|C0184661
There were no significant differences between the intervention and control group.,There differences intervention control group.,G0000000|C1705241|C0886296|C0243148|C0441833
"PLWH at an HIV clinic in Mombasa, Kenya, were screened according to the following eligibility criteria: adults on ART for at least 1 month, with a pain or symptom score of 3–5 (from a possible range of 0 (best) to 5 (worst)) on the African Palliative Care Association Palliative Outcome Scale (APOS) [15, 16].","PLWH HIV clinic Mombasa, Kenya, screened eligibility criteria: adults ART 1 month, pain symptom score 3–5 (from range 0 (best) 5 (worst)) African Palliative Care Association Palliative Outcome Scale (APOS) [15, 16].",G0000000|C0019682|C0002424|G0000000|C0022558|C0220908|C0013893|C0243161|C0001675|C0003826|G0000000|C0332177|C0030193|C1457887|C0449820|G0000000|G0000000|C1514721|G0000000|C1522427|G0000000|C1522166|C0027567|C0587605|C1947933|C0004083|C0587605|C1274040|C0175659|G0000000|C0450371|C0450371
"We identified a cohort of 148 female BRCA1 or BRCA2 mutation carriers (115 and 33, respectively) who previously were treated for unilateral invasive breast cancer stages I–IIIa.","We identified cohort 148 female BRCA1 BRCA2 mutation carriers (115 33, respectively) treated unilateral invasive breast cancer stages I–IIIa.",G0000000|C0205396|C0599755|C1442061|C0015780|G0000000|G0000000|C0026882|C0007294|C1442061|C0450371|G0000000|C1522326|C0205092|C0205281|C0006141|C0006826|C1306673|G0000000
"Patients were also required to receive their care at MGH, be ≥ 18 years of age, have no history of therapy for metastatic disease, have an Eastern Cooperative Oncology Group performance status of 0 to 2, and be able to read and respond to questions in English or complete questionnaires with minimal assistance.","Patients required receive care MGH, ≥ 18 age, history therapy metastatic disease, Eastern Cooperative Oncology Group performance status 0 2, read respond questions English complete questionnaires minimal assistance.",C0030705|C1514873|C1514756|C1947933|G0000000|G0000000|C0450371|C0001779|C0019664|C0039798|C0036525|C0012634|C1707877|C0679729|C0027651|C0441833|C0597198|C0449438|G0000000|G0000000|C0034754|G0000000|C1522634|C0376245|C0205197|C0034394|C0547040|C0018896
"After 31 months of enrollment, the eligibility criteria were liberalized to include patients with presumed infection (identical host and clinical criteria, but identification of organism not necessary), and to include patients with neutropenia due to underlying marrow disease (eg, aplastic anemia).","After 31 months enrollment, eligibility criteria liberalized patients presumed infection (identical host clinical criteria, identification organism necessary), patients neutropenia underlying marrow disease (eg, aplastic anemia).",G0000000|C0450371|C0439231|C1516879|C0013893|C0243161|G0000000|C0030705|G0000000|C0009450|C0205280|C1167395|C0205210|C0243161|C0020792|C0029235|G0000000|C0030705|C0023530|G0000000|C0086590|C0012634|C0013715|C0334079|C0002871
"STUDY DESIGN—Randomised, double blind, placebo controlled trial of 163 children admitted to hospital with asthma who were unresponsive to nebulised salbutamol.","STUDY DESIGN—Randomised, double blind, placebo controlled trial 163 children admitted hospital asthma unresponsive nebulised salbutamol.",C0557651|G0000000|C0205173|C0150108|C0032042|C2587213|C0008976|C1442061|C0008059|C0184666|C0019994|C0004096|C0205269|G0000000|C0001927
Dyads were excluded if either the newborn or mother had an extended hospital stay of 7 days or more after childbirth.,Dyads excluded newborn mother extended hospital stay 7 days childbirth.,C0870454|C1554077|C0021289|C0026591|C0231448|C0019994|G0000000|G0000000|C0439228|C0005615
Inclusion criteria are as follows: - maximum tumor diameter less than 4 cm in the pathohistological specimen irrespective of histological grading (pT1 or pT2) - concomitant histological verification of a singular ipsilateral lymph node metastasis less than 3 cm in diameter (pN1) without penetration of the lymph node's capsule and without presence of lymphangiosis carcinomatosa - radical resection of the tumor within adequate resection margins (R0) - written informed consent from the patient - adequate performance status ECOG Index ≤ 2 Patients younger than 18 and pregnant women are to be excluded.,Inclusion criteria follows: - maximum tumor diameter 4 cm pathohistological specimen irrespective histological grading (pT1 pT2) - concomitant histological verification singular ipsilateral lymph node metastasis 3 cm diameter (pN1) penetration lymph node's capsule presence lymphangiosis carcinomatosa - radical resection tumor adequate resection margins (R0) - written informed consent patient - adequate performance status ECOG Index ≤ 2 Patients 18 pregnant women excluded.,C0007637|C0243161|C0332283|G0000000|C0806909|C0027651|C1301886|G0000000|G0000000|G0000000|C0370003|G0000000|C0205462|C0441800|C0030899|C0030899|G0000000|C0521115|C0205462|C0237944|C0205171|C0441989|C0024202|C0746922|C0027627|G0000000|G0000000|C1301886|G0000000|C0205321|C0024202|C0746922|C0006935|C0150312|G0000000|G0000000|G0000000|C0302912|C0015252|C0027651|C0205410|C0015252|C0205284|C1425688|G0000000|C0043266|C1522154|C1511481|C0030705|G0000000|C0205410|C0597198|C0449438|C0430797|C0918012|G0000000|G0000000|C0030705|C0450371|C0549206|C0043210|C1554077
"Patients with no prior treatment for advanced/metastatic disease, Eastern Cooperative Oncology Group (ECOG) performance status 0–2, adequate organ function, and measurable or nonmeasurable but evaluable disease were included in the study.","Patients prior treatment advanced/metastatic disease, Eastern Cooperative Oncology Group (ECOG) performance status 0–2, adequate organ function, measurable nonmeasurable evaluable disease included study.",C0030705|C0332152|C0039798|C0205179|C0012634|C1707877|C0679729|C0027651|C0441833|C0430797|C0597198|C0449438|G0000000|C0205410|C0178784|C0031843|C1513040|C1518373|C1516986|C0012634|C0332257|C0557651
"We identified 3,889 female patients with stages I-III breast cancer who were treated at The University of Texas MD Anderson Cancer Center from 1997 to 2009.","We identified 3,889 female patients stages I-III breast cancer treated The University Texas MD Anderson Cancer Center 1997 2009.",G0000000|C0205396|C1442061|C0015780|C0030705|C1306673|C0021966|C0006141|C0006826|C1522326|G0000000|C0041740|C0039711|G0000000|G0000000|C0006826|C0205099|G0000000|G0000000
"Fifty newly diagnosed breast cancer survivors were recruited through a hospital-based tumor registry and randomized to a 6-month, home-based exercise program (n=25) or a usual care group (n=25).","Fifty newly diagnosed breast cancer survivors recruited hospital-based tumor registry randomized 6-month, home-based exercise program (n=25) usual care (n=25).",C3816723|C0750546|C0011900|C0006141|C0006826|C0206194|G0000000|C0019994|C0027651|C0034975|C0034656|C0332177|C0442519|C0015259|C1709697|C0369718|C3538928|C1947933|C0369718
Patients with serum C-telopeptide (CTx) levels ≤600 ng/L after ≥3 months of 3–4 weekly IV pamidronate were switched to 12 weekly therapy for 48 weeks.,Patients serum C-telopeptide (CTx) levels ≤600 ng/L ≥3 months 3–4 weekly IV pamidronate switched 12 weekly therapy 48 weeks.,C0030705|C0229671|C0631180|C0631180|C0441889|G0000000|C0439297|G0000000|C0439231|G0000000|C0332174|C0022326|C0043603|C1707719|C0450371|C0332174|C0039798|C0450371|C0439230
"The inclusion criteria are as following: patient consent to participate in the study, no sensitivity to retinoids, no pregnancy, not willing to become pregnant, and absence of hormonal disorders in patients.","The inclusion criteria following: patient consent participate study, sensitivity retinoids, pregnancy, pregnant, absence hormonal disorders patients.",G0000000|C0007637|C0243161|C0231290|C0030705|C1511481|G0000000|C0557651|C0020517|C0035339|C0032961|C0549206|C0332197|C0458083|C0012634|C0030705
"Criteria for exclusion were as follows: infantile onset (<1 year); previous history of macro-hematuria, hepatitis B, hepatitis C, or HIV infection; positivity of any marker of autoimmunity (ANA, nDNA, ANCA); and low C3 levels.","Criteria exclusion follows: infantile onset (<1 year); previous history macro-hematuria, hepatitis B, hepatitis C, HIV infection; positivity marker autoimmunity (ANA, nDNA, ANCA); low C3 levels.",C0243161|C0680251|C0332283|C0231330|C0206132|G0000000|C0439234|C0205156|C0019664|C2984010|C0019158|G0000000|C0019158|G0000000|C0019682|C0009450|C0439178|C0005516|C0004364|G0000000|C1179920|C0103647|C0205251|G0000000|C0441889
Inclusion criteria for the study are as follows: • Orthodontic indication for skeletal anchorage • Adequate bone quantity for a palatal implant in the lateral cephalogram • Good oral hygiene and normal wound healing capacity • Written informed consent Patients with cheilognathopalatoschisis and other syndromes associated with craniofacial anomalies are to be excluded.,Inclusion criteria study follows: • Orthodontic indication skeletal anchorage • Adequate bone quantity palatal implant lateral cephalogram • Good oral hygiene normal wound healing capacity • Written informed consent Patients cheilognathopalatoschisis syndromes craniofacial anomalies excluded.,C0007637|C0243161|C0557651|C0332283|G0000000|C0332276|C0392360|C0037253|C2825961|G0000000|C0205410|C0262950|C1265611|C0700374|C0021102|C0205093|C1962944|G0000000|C0205170|C0442027|C0020405|C0205307|C0043250|C0043240|C1516240|G0000000|C0043266|C1522154|C1511481|C0030705|C0266090|C0039082|C0596392|C0000769|C1554077
"We identified women from clinical records in 12 NHS hospitals as having had a cervical histology sample taken (by a punch biopsy at colposcopy or excisional treatment, or both) between January 1987 and December 2009.","We identified women clinical records 12 NHS hospitals cervical histology sample (by punch biopsy colposcopy excisional treatment, both) January 1987 December 2009.",G0000000|C0205396|C0043210|C0205210|C0034869|C0450371|C0796085|C0019994|C0027530|C0019638|C0370003|G0000000|C0182555|C0005558|C0009417|C0728940|C0039798|G0000000|C3829466|G0000000|C3830550|G0000000
"We retrospectively reviewed 31 patients with 32 Grade I intracompartmental chondrosarcomas of the long bones of the appendicular skeleton treated with either resection (15 lesions) or extended intralesional curetting (17) at a minimum followup of 2 years (median, 55 months; range, 24–203 months).","We retrospectively reviewed 31 patients 32 Grade I intracompartmental chondrosarcomas bones appendicular skeleton treated resection (15 lesions) extended intralesional curetting (17) minimum followup 2 (median, 55 months; range, 24–203 months).",G0000000|G0000000|C0282443|C0450371|C0030705|C0450371|C0441800|C0021966|G0000000|C0008479|C0262950|G0000000|C0037253|C1522326|C0015252|C0450371|C0221198|C0231448|C1512954|C0180236|C0450371|C1524031|C0589120|G0000000|C0549183|C0450371|C0439231|C1514721|G0000000|C0439231
"Eligible participants were physically inactive (< 90 min/wk of physical activity in the past six months and no strength training in the past year), postmenopausal women, diagnosed 0.5-4.0 years prior to enrollment with hormone receptor positive Stage I to III breast cancer, and taking an AI for at least six months.","Eligible participants physically inactive (< 90 min/wk physical activity months strength training year), postmenopausal women, diagnosed 0.5-4.0 prior enrollment hormone receptor positive Stage I III breast cancer, AI months.",C1548635|C0679646|G0000000|C0205254|G0000000|C0450371|C0702093|C0031809|C0205177|C0439231|C0237897|C0040607|C0439234|C0232970|C0043210|C0011900|G0000000|C0332152|C1516879|C0019932|C0597357|C0439178|C0205390|C0021966|C0439070|C0006141|C0006826|C0003353|C0439231
"In the PLCO trial, two screenings were offered, and participants ranged from 55 to 74 years of age.","In PLCO trial, screenings offered, participants ranged 55 74 age.",G0000000|C1514515|C0008976|C0220908|C1444648|C0679646|C1514721|C0450371|C0450371|C0001779
"As shown in Figure 1, a total of 331 breast cancer patients were assessed for eligibility.","As Figure 1, total 331 breast cancer patients assessed eligibility.",G0000000|G0000000|G0000000|C0439175|C1442061|C0006141|C0006826|C0030705|C1516048|C0013893
Patients unable to give informed consent and patients with an active psychotic disorder or a serious cognitive disorder are not eligible for inclusion.,Patients unable informed consent patients active psychotic disorder cognitive disorder eligible inclusion.,C0030705|C1299582|C1522154|C1511481|C0030705|C0205177|C0004936|C0012634|C1516691|C0012634|C1548635|C0007637
"Therefore, a total of 91 evaluable patients were recruited from four centres in Germany from March 2004 to December 2006 (cohort I, n=40; cohort II, n=51).","Therefore, total 91 evaluable patients recruited centres Germany March 2004 December 2006 (cohort I, n=40; cohort II, n=51).",G0000000|C0439175|C0450371|C1516986|C0030705|G0000000|C0205099|C0017480|C3829202|G0000000|C3830550|G0000000|C0599755|C0021966|C0369718|C0599755|G0000000|C0369718
"After lumpectomy or mastectomy, women 60 years of age or younger with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive CEF, EC/T, or AC/T for 6 months.","After lumpectomy mastectomy, women 60 age axillary node-positive high-risk node-negative breast cancer randomly assigned receive CEF, EC/T, AC/T 6 months.",G0000000|C0851238|C0024881|C0043210|C0450371|C0001779|C0004454|C0746319|C0332167|C0678034|C0006141|C0006826|G0000000|C1516050|C1514756|C0060133|C3890233|C1879500|G0000000|C0439231
"A majority of patients have locally advanced, liver restricted disease (Barcelona Clinic Liver Cancer (BCLC) staging system intermediate stage).","A majority patients locally advanced, liver restricted disease (Barcelona Clinic Liver Cancer (BCLC) staging system intermediate stage).",G0000000|C0680220|C0030705|C1517927|C0205179|C0023884|C0443288|C0012634|G0000000|C0002424|C0023884|C0006826|G0000000|C0332305|C0449913|C0205103|C0205390
"Pregnant women aged 14−25 years (n=1,047) were randomly assigned to either standard or group care.","Pregnant women aged 14−25 (n=1,047) randomly assigned standard care.",C0549206|C0043210|C0001779|G0000000|C0369718|G0000000|C1516050|C1442989|C1947933
"At the onset of the study, eligible patients were those of any age with (1) neutropenia, defined as absolute neutrophil count (ANC) <500 cells per µL, due to aggressive chemotherapy or hematopoietic stem cell transplantation and (2) proven or probable bacterial or fungal infection.","At onset study, eligible patients age (1) neutropenia, defined absolute neutrophil count (ANC) <500 cells µL, aggressive chemotherapy hematopoietic stem cell transplantation (2) proven probable bacterial fungal infection.",G0000000|C0206132|C0557651|C1548635|C0030705|C0001779|G0000000|C0023530|C1704788|C0205344|C0027950|C0750480|C0948762|C1442061|C0007634|G0000000|C0001807|C0013216|C0018957|C0242767|C0007634|C0040732|G0000000|C0456369|C0033204|C0521009|C0016832|C0009450
"Other eligibility requirements were an age at diagnosis of under 31 years; completion of induction therapy, autologous stem-cell transplantation, and radiotherapy; achievement of at least a partial response at the time of evaluation before autologous stem-cell transplantation; autologous stem-cell transplantation performed within 9 months after the initiation of induction therapy; enrollment between day 50 and day 100 after the final autologous stem-cell transplantation; absence of progressive disease; and adequate organ function and a life expectancy of at least 2 months.","Other eligibility requirements age diagnosis 31 years; completion induction therapy, autologous stem-cell transplantation, radiotherapy; achievement partial response time evaluation autologous stem-cell transplantation; autologous stem-cell transplantation performed 9 months initiation induction therapy; enrollment day 50 day 100 final autologous stem-cell transplantation; absence progressive disease; adequate organ function life expectancy 2 months.",G0000000|C0013893|C1514873|C0001779|C0011900|C0450371|C0439234|C0205197|C0205263|C0039798|C0439859|C0038250|C0040732|C0034619|C0001072|C0728938|C0871261|C0040223|C0220825|C0439859|C0038250|C0040732|C0439859|C0038250|C0040732|C0884358|G0000000|C0439231|C0589507|C0205263|C0039798|C1516879|C0332173|C0450371|C0332173|C1442061|C0205088|C0439859|C0038250|C0040732|C0332197|C0205329|C0012634|C0205410|C0178784|C0031843|C0376558|C0679138|G0000000|C0439231
"METHODS: From 2004 to 2006, a total of 1024 Chinese patients (aged 35 to 64 years) with severe chronic atrophic gastritis, intestinal metaplasia or dysplasia were randomly assigned to receive 200 mg of celecoxib twice daily or placebo in Linqu County (Shandong Province, China), a high-risk area of gastric cancer.","METHODS: From 2004 2006, total 1024 Chinese patients (aged 35 64 years) severe chronic atrophic gastritis, intestinal metaplasia dysplasia randomly assigned receive 200 celecoxib daily placebo Linqu County (Shandong Province, China), high-risk gastric cancer.",C0025663|G0000000|G0000000|G0000000|C0439175|G0000000|C0008120|C0030705|C0001779|C0450371|C0450371|C0439234|C0205082|C0205191|C0151514|C0017152|C0021853|C0025568|C0334044|G0000000|C1516050|C1514756|C1442061|C0538927|C0332173|C0032042|G0000000|C0079170|G0000000|C1514578|C0008115|C0332167|C0038351|C0006826
"Between March 25, 2009, and July 12, 2010, 202 patients recruited from 14 sites were randomized to capecitabine–cisplatin plus either placebo (n = 102) or bevacizumab (n = 100; Fig.","Between March 25, 2009, July 12, 2010, 202 patients recruited 14 sites randomized capecitabine–cisplatin placebo (n = 102) bevacizumab (n = 100; Fig.",G0000000|C3829202|C0450371|G0000000|C3829447|C0450371|G0000000|C1442061|C0030705|G0000000|C0450371|C0205145|C0034656|G0000000|C0032042|C0369718|G0000000|C1442061|C0796392|C0369718|G0000000|C1442061|C0349966
"We recruited 51 interested family physicians (n = 17), general surgeons (n = 16), and oncologists (n = 18) in Southern Ontario, Canada.","We recruited 51 family physicians (n = 17), surgeons (n = 16), oncologists (n = 18) Southern Ontario, Canada.",G0000000|G0000000|C0450371|C0015576|C0031831|C0369718|G0000000|C0450371|C0582175|C0369718|G0000000|C0450371|C0259990|C0369718|G0000000|C0450371|C1710133|C0029040|C0006823
Patients were excluded if they failed to give consent or were not willing to complete the postendoscopy questionnaire.,Patients excluded failed consent complete postendoscopy questionnaire.,C0030705|C1554077|C0231175|C1511481|C0205197|G0000000|C0034394
"The Nabholtz study also enrolled 392 patients, including 220 (56%) true anthracycline-resistant patients, as opposed to 70 (40%) anthracycline-resistant patients in our study.","The Nabholtz study enrolled 392 patients, including 220 (56%) true anthracycline-resistant patients, opposed 70 (40%) anthracycline-resistant patients study.",G0000000|G0000000|C0557651|G0000000|C1442061|C0030705|C0332257|C1442061|C0450371|C0205238|C0003234|C0030705|G0000000|C0450371|C0450371|C0003234|C0030705|C0557651
The study group (n=20) was comprised of nine women and eleven men.,The study (n=20) comprised women eleven men.,G0000000|C0557651|C0369718|C2700400|C0043210|C0205457|C0025266
"Exclusion criteria included age <20 years, treatment for dyslipidemia within the preceding 3 months, current treatment with progesterone or other hormone therapy within the previous 3 months, familial hypercholesterolemia, acute coronary syndrome, congestive heart failure (New York Heart Association class II or greater), liver dysfunction, chronic kidney disease requiring regular hemodialysis, endocrine disease, secondary hypertension, and administration of agents affecting lipid metabolism.","Exclusion criteria included age <20 years, treatment dyslipidemia preceding 3 months, current treatment progesterone hormone therapy previous 3 months, familial hypercholesterolemia, acute coronary syndrome, congestive heart failure (New York Heart Association class II greater), liver dysfunction, chronic kidney disease requiring regular hemodialysis, endocrine disease, secondary hypertension, administration agents lipid metabolism.",C0680251|C0243161|C0332257|C0001779|C0450371|C0439234|C0039798|C0242339|C0332152|G0000000|C0439231|C0521116|C0039798|C0033308|C0019932|C0039798|C0205156|G0000000|C0439231|C0015576|C0020443|C0205178|C0018787|C0039082|C0742742|C0018787|C0231174|C0205314|G0000000|C0018787|C0004083|C0456387|G0000000|C1704243|C0023884|C0031847|C0205191|C0022646|C0012634|G0000000|C0205272|C0019004|C0014136|C0012634|C0027627|C0020538|C0001554|C0450442|C0023779|C0025519
"Briefly, healthy girls and young women aged 9-25 y at the time of first vaccination in the study were stratified by age (9-14, 15-19, 20-25 y) and randomized (1:1:1:1) to receive 3 doses of the licensed HPV-16/18 AS04-adjuvanted vaccine formulation (containing 20 µg each of HPV-16 and −18 L1 VLPs adjuvanted with AS04) at 0, 1 and 6 months, 2 doses of the licensed vaccine formulation at 0 and 6 months, 2 doses of an alternative vaccine formulation (containing 40 µg each of HPV-16 and −18 L1 VLPs adjuvanted with AS04) at 0 and 6 months, or 2 doses of the alternative vaccine formulation at 0 and 2 months.","Briefly, healthy girls women aged 9-25 time vaccination study stratified age (9-14, 15-19, 20-25 y) randomized (1:1:1:1) receive 3 doses licensed HPV-16/18 AS04-adjuvanted vaccine formulation (containing 20 µg HPV-16 −18 L1 VLPs adjuvanted AS04) 0, 1 6 months, 2 doses licensed vaccine formulation 0 6 months, 2 doses alternative vaccine formulation (containing 40 µg HPV-16 −18 L1 VLPs adjuvanted AS04) 0 6 months, 2 doses alternative vaccine formulation 0 2 months.",G0000000|C3898900|C0870604|C0043210|C0001779|C0450371|C0040223|C0042196|C0557651|C0205363|C0001779|C0450371|C0450371|C0450371|G0000000|C0034656|G0000000|C1514756|G0000000|C0178602|C0023636|C0021344|C0001551|C0042210|C0524527|C0332256|C0450371|G0000000|C0021344|G0000000|C0441916|C0262304|C0001551|G0000000|G0000000|G0000000|G0000000|C0439231|G0000000|C0178602|C0023636|C0042210|C0524527|G0000000|G0000000|C0439231|G0000000|C0178602|C1523987|C0042210|C0524527|C0332256|C0450371|G0000000|C0021344|G0000000|C0441916|C0262304|C0001551|G0000000|G0000000|G0000000|C0439231|G0000000|C0178602|C1523987|C0042210|C0524527|G0000000|G0000000|C0439231
This randomized double-blind placebo-controlled clinical trial was performed among 42 pregnant women aged 18–40 years who were at week 25 of gestation.,This randomized double-blind placebo-controlled clinical trial performed 42 pregnant women aged 18–40 week 25 gestation.,G0000000|C0034656|C0013072|C1706408|C0205210|C0008976|C0884358|C0450371|C0549206|C0043210|C0001779|G0000000|C0332174|C0450371|C0032961
Most participants had stage IIIB disease.,Most participants stage IIIB disease.,C0205393|C0679646|C0205390|G0000000|C0012634
"Thus, our study also included students who entered the schools at any year during the course of the study and who were in fifth grade at the end of the study.","Thus, study included students entered schools study grade study.",G0000000|C0557651|C0332257|C0038492|C1521975|C0036375|C0557651|C0441800|C0557651
"Eligibility criteria for participants included: a) aged ≥21 years and diagnosed with Stage 0–3 breast cancer in the past 5 years, b) completed surgery (patients receiving on-going chemotherapy, radiation or hormone treatment were eligible), c) able to read and speak English; d) able to walk half-mile without stopping, e) sedentary: <30 minutes/week of vigorous PA or <90 minutes/week of moderate-intensity PA for the past six months, and f) access to a telephone and were willing to receive calls.","Eligibility criteria participants included: a) aged ≥21 diagnosed Stage 0–3 breast cancer 5 years, b) completed surgery (patients receiving on-going chemotherapy, radiation hormone treatment eligible), c) read speak English; d) walk half-mile stopping, e) sedentary: <30 minutes/week vigorous PA <90 minutes/week moderate-intensity PA months, f) access telephone receive calls.",C0013893|C0243161|C0679646|C0332257|G0000000|C0001779|G0000000|C0011900|C0205390|G0000000|C0006141|C0006826|G0000000|C0439234|G0000000|C0205197|C0038894|C0030705|C1514756|C1720176|C0013216|C0034519|C0019932|C0039798|C1548635|G0000000|C0034754|C0234856|C0376245|C0073187|C0080331|C2825407|C0723457|G0000000|C0205254|C0450371|C0556975|G0000000|C0030428|C0450371|C0556975|C0205081|C0030428|C0439231|C0016327|C0444454|C0039457|C1514756|C0679006
"Subjects could not report more than 1 month of gas-permeable, soft bifocal, or orthokeratology contact lens wear or more than 1 month of myopia control (including atropine or bifocal spectacles).","Subjects report 1 month gas-permeable, soft bifocal, orthokeratology contact lens wear 1 month myopia control (including atropine bifocal spectacles).",C0681850|C0684224|G0000000|C0332177|C0017110|C0205358|C1275647|C1533088|C0332158|C0023317|G0000000|G0000000|C0332177|C0027092|C0243148|C0332257|C0004259|C1275647|C0015421
PARTICIPANTS: A sample of women aged 18-69 years who were listed as patients of the clinics but who had not had a Papanicolaou test (Pap test) within the 3 years before the start of the study.,PARTICIPANTS: A sample women aged 18-69 listed patients clinics Papanicolaou test (Pap test) 3 start study.,C0679646|G0000000|C0370003|C0043210|C0001779|C0450371|C0745732|C0030705|C0442592|G0000000|C0022885|C1740167|C0022885|G0000000|C0439659|C0557651
Participants 812 patients aged 50 and over with osteoarthritis of hips or knees (or both) and pain or disability (or both).,Participants 812 patients aged 50 osteoarthritis hips knees (or both) pain disability (or both).,C0679646|C1442061|C0030705|C0001779|C0450371|C0029408|C0019552|C0022742|G0000000|G0000000|C0030193|C0231170|G0000000|G0000000
"The ethnicity breakdown of the sample was 63% European American, 9% African American, 10% Latino, 4% Native American, and 14% multiracial.","The ethnicity breakdown sample 63% European American, 9% African American, 10% Latino, 4% Native American, 14% multiracial.",G0000000|C0015031|C0443161|C0370003|C0450371|C0239307|C0596070|G0000000|C0027567|C0596070|C0450371|C0086528|G0000000|C0302891|C0596070|C0450371|C1881928
"We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or without bevacizumab in patients with previously untreated metastatic melanoma.","We conducted placebo-controlled, double-blind phase II study carboplatin paclitaxel bevacizumab patients untreated metastatic melanoma.",G0000000|C0004927|C1706408|C0013072|C0205390|G0000000|C0557651|C0079083|C0144576|C0796392|C0030705|C0332155|C0036525|C0025202
"Those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse); patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician's point of view, prevented the patient from following the treatment protocol; women who were pregnant or nursing; and those who declined to participate.","Those excluded patients severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder alcohol and/or drug abuse); patients severe axis II psychiatric disorders medical disorders that, clinician's view, prevented patient treatment protocol; women pregnant nursing; declined participate.",G0000000|C1554077|C0030705|C0205082|C0004457|C0021966|C0205487|C0012634|C0011265|C0036341|G0000000|C0012634|C0001962|G0000000|C0013227|C0013146|C0030705|C0205082|C0004457|G0000000|C0205487|C0012634|C0199168|C0012634|G0000000|C0871685|C0449911|C0309872|C0030705|C0039798|C0442711|C0043210|C0549206|C0006147|G0000000|G0000000
Inclusion criteria were: 1) originally diagnosed with Stage 0 – II breast cancer; 2) completed local and/or adjuvant cancer therapy (with the exception of hormonal therapy) at least 6 months previously; 3) age 40 – 65; 4) post-menopausal; 5) no other cancer in last 5 years; and 6) experiencing persistent cancer-related fatigue.,Inclusion criteria were: 1) originally diagnosed Stage 0 – II breast cancer; 2) completed local and/or adjuvant cancer therapy (with exception hormonal therapy) 6 months previously; 3) age 40 – 65; 4) post-menopausal; 5) cancer 5 years; 6) experiencing persistent cancer-related fatigue.,C0007637|C0243161|G0000000|G0000000|G0000000|C0011900|C0205390|G0000000|G0000000|G0000000|C0006141|C0006826|G0000000|C0205197|C0205276|G0000000|C0001551|C0006826|C0039798|G0000000|C1554961|C0458083|C0039798|G0000000|C0439231|G0000000|G0000000|C0001779|C0450371|G0000000|C0450371|G0000000|C0232970|G0000000|C0006826|G0000000|C0439234|G0000000|C0237607|C0205322|C2826292|C0015672
Eligible subjects were aged 8 months (±14 days) at the time of randomisation; not expected to leave the study location for >1 week over the next 3 months or for >1 month over the next 12 months; has a legal guardian capable of providing informed consent.,Eligible subjects aged 8 months (±14 days) time randomisation; expected leave study location >1 week 3 months >1 month 12 months; legal guardian capable providing informed consent.,C1548635|C0681850|C0001779|G0000000|C0439231|G0000000|C0439228|C0040223|C0034656|C1517001|G0000000|C0557651|C0450429|G0000000|G0000000|C0439231|G0000000|C0450371|C0439231|C1301860|C0023226|C2698977|C1999230|C1522154|C1511481
"The trial was carried out in Sangam Vihar, a peri-urban population in New Delhi, India, from April 2002 to April 2004.","The trial carried Sangam Vihar, peri-urban population New Delhi, India, April 2002 April 2004.",G0000000|C0008976|C0206243|G0000000|G0000000|C0347985|C0032659|C0205314|G0000000|C0021201|C3715024|G0000000|C3715024|G0000000
"The eligibility criteria to this study are: 1) the patients are aged 3–16 years at the time of recruitment, 2) the treatment regimen includes vincristine and 3) the patient is treated in either of the designated hospitals (Turku University Hospital or Tampere University Hospital, Finland).","The eligibility criteria study are: 1) patients aged 3–16 time recruitment, 2) treatment regimen includes vincristine 3) patient treated designated hospitals (Turku University Hospital Tampere University Hospital, Finland).",G0000000|C0013893|C0243161|C0557651|G0000000|G0000000|C0030705|C0001779|G0000000|C0040223|C2949735|G0000000|C0039798|C0040808|C0332257|C0042679|G0000000|C0030705|C1522326|C1524084|C0019994|G0000000|C0041740|C0019994|G0000000|C0041740|C0019994|C0016132
"Exclusion criteria included occurrence of unbearable diarrhea, taking another drug for treatment of diarrhea during the study and unwilling to participate in the study at any time.","Exclusion criteria included occurrence unbearable diarrhea, drug treatment diarrhea study unwilling participate study time.",C0680251|C0243161|C0332257|C0243132|G0000000|C0011991|C0013227|C0039798|C0011991|C0557651|C0558080|G0000000|C0557651|C0040223
"We randomized 7,466 healthy women 18 to 25 years of age to HPV16/18 or hepatitis A vaccine (follow-up, 50.4 months).","We randomized 7,466 healthy women 18 25 age HPV16/18 hepatitis A vaccine (follow-up, 50.4 months).",G0000000|C0034656|C1442061|C3898900|C0043210|C0450371|C0450371|C0001779|C0450371|C0019158|G0000000|C0042210|C0589120|C0450371|C0439231
The mean age of participating patients was 41.6 years (range 18–65 years) and 69 of the 81 patients were female.,The age participating patients 41.6 (range 18–65 years) 69 81 patients female.,G0000000|C0001779|C0679823|C0030705|C0450371|C1514721|G0000000|C0439234|C0450371|C0450371|C0030705|C0015780
Children previously discharge from the study with a recovered outcome that later relapsed and presented again at the one of the participating HCs with a new episode of SAM were also not eligible for enrolment in the study a second time.,Children discharge study recovered outcome relapsed participating HCs episode SAM eligible enrolment study time.,C0008059|C0012621|C0557651|C0521108|C1274040|C0205336|C0679823|G0000000|C0332189|C0036002|C1548635|C1516879|C0557651|C0040223
"Patients of American Society of Anaesthesiologists physical status I and II, age ranging from 20 to 60 years of either sex with preoperative Glasgow coma score of 15 were included in the study.","Patients American Society Anaesthesiologists physical status I II, age ranging 20 60 sex preoperative Glasgow coma score 15 included study.",C0030705|C0596070|C0037455|C0334910|C0031809|C0449438|C0021966|G0000000|C0001779|C1514721|C0450371|C0450371|C0009253|C0445204|G0000000|C0009421|C0449820|C0450371|C0332257|C0557651
"The exclusion criteria included concurrent major health problems that could affect their participation in an exercise program, including uncontrolled hypertension, cardiovascular disease, acute or chronic respiratory disease, and cognitive dysfunction.","The exclusion criteria included concurrent major health affect participation exercise program, including uncontrolled hypertension, cardiovascular disease, acute chronic respiratory disease, cognitive dysfunction.",G0000000|C0680251|C0243161|C0332257|C0205420|C0205082|C0018684|C0001721|C0679823|C0015259|C1709697|C0332257|C0205318|C0020538|C0007226|C0012634|C0205178|C0205191|C0521346|C0012634|C1516691|C0031847
"Children who had signs of severe malnutrition, including having a WHZ < −3 and/or edema, chronic illness, cardiac disease, congenital abnormalities, cancer, or those who had been discharged from the nutritional rehabilitation unit, were not eligible for the study.","Children signs severe malnutrition, including WHZ < −3 and/or edema, chronic illness, cardiac disease, congenital abnormalities, cancer, discharged nutritional rehabilitation unit, eligible study.",C0008059|C0220912|C0205082|C0162429|C0332257|G0000000|G0000000|G0000000|G0000000|C0013604|C0205191|C0221423|C0018787|C0012634|C0009678|C0000768|C0006826|C0030685|C1521739|C0034991|C0439148|C1548635|C0557651
All subjects were genetically unrelated ethnic Han Chinese from AnXi or the surrounding regions.,All subjects genetically unrelated ethnic Han Chinese AnXi surrounding regions.,G0000000|C0681850|G0000000|C0445356|C0015031|C1551910|C0008120|G0000000|C1282914|C0017446
"Patients with cystic fibrosis (CF), who had documented clinical, radiologic, genotypic features and abnormal sweat test results (sweat sodium and chloride >60 mmol/L) [13], had been excluded.","Patients cystic fibrosis (CF), documented clinical, radiologic, genotypic features abnormal sweat test (sweat sodium chloride >60 mmol/L) [13], excluded.",C0030705|C0205207|C0016059|C0009738|C1301725|C0205210|C0034599|C0017431|C1521970|C0205161|C0038984|C0022885|C0038984|C0037473|C0008203|G0000000|C0450371|C1554077
"In addition, women were excluded if they reported current or recent (within the past 3 months) use of the following medications: oral or systemic corticosteroids, hormones (estrogen, progestin, oral contraceptives), herbal or botanical supplements with possible hormonal or EGCG effects, or if they reported use of GnRH analogues or Depo-Provera within the past 6 months.","In addition, women excluded reported current (within 3 months) medications: oral systemic corticosteroids, hormones (estrogen, progestin, oral contraceptives), herbal botanical supplements hormonal EGCG effects, reported GnRH analogues Depo-Provera 6 months.",G0000000|C0332287|C0043210|C1554077|C0684224|C0521116|G0000000|G0000000|C0439231|C0013227|C0442027|C0205373|C0001617|C0019932|C0014939|C0033306|C0442027|C0009871|C3146288|C1456557|C0242295|C0458083|C0059438|C1280500|C0684224|C0023610|C0243071|C0699700|G0000000|C0439231
"The participant inclusion eligibility criteria are as follows: (1) aged 18 or above, (2) living in Australia at the time of the study, (3) easy access to the Internet and email on a regular basis, (4) doctor diagnosis of asthma, and (5) adequate English reading and written ability.","The participant inclusion eligibility criteria follows: (1) aged 18 above, (2) living Australia time study, (3) easy access Internet email regular basis, (4) doctor diagnosis asthma, (5) adequate English reading written ability.",G0000000|C0679646|C0007637|C0013893|C0243161|C0332283|G0000000|C0001779|C0450371|C1282910|G0000000|C0376558|C0004340|C0040223|C0557651|G0000000|C0332219|C0444454|C0282111|C0013849|C0205272|C1527178|G0000000|C0031831|C0011900|C0004096|G0000000|C0205410|C0376245|C0034754|C0043266|C0085732
"Exclusion criteria were cancer infiltrating adjacent organs assessed by computed tomography or magnetic resonance imaging, cardiovascular dysfunction (New York Heart Association class > 3), respiratory dysfunction (arterial Po2 < 70 mmHg), hepatic dysfunction (Child-Pugh class C), ongoing infection, and plasma neutrophil level less than 2.0 × 109/L.","Exclusion criteria cancer infiltrating adjacent organs assessed computed tomography magnetic resonance imaging, cardiovascular dysfunction (New York Heart Association class > 3), respiratory dysfunction (arterial Po2 < 70 mmHg), hepatic dysfunction (Child-Pugh class C), ongoing infection, plasma neutrophil level 2.0 × 109/L.",C0680251|C0243161|C0006826|C0332448|C0205117|C0178784|C1516048|C1441526|C0040395|C0024488|C0231881|C0011923|C0007226|C0031847|C0205314|G0000000|C0018787|C0004083|C0456387|G0000000|G0000000|C0521346|C0031847|C0003842|C1418945|G0000000|C0450371|C0439475|C0205054|C0031847|C4050412|C0456387|G0000000|C0549178|C0009450|C0032105|C0027950|C0441889|G0000000|G0000000|C1442061
Forty adult female breast cancer survivors who received adjuvant chemotherapy for stage I and II breast cancer were recruited for the study through letters asking for volunteers mailed to survivors from the Comprehensive Breast Program at Dartmouth-Hitchcock Medical Center.,Forty adult female breast cancer survivors received adjuvant chemotherapy stage I II breast cancer recruited study letters volunteers mailed survivors Comprehensive Breast Program Dartmouth-Hitchcock Medical Center.,C3816449|C0001675|C0015780|C0006141|C0006826|C0206194|C1514756|C0001551|C0013216|C0205390|C0021966|G0000000|C0006141|C0006826|G0000000|C0557651|C0282413|C0042960|C0024492|C0206194|C1880156|C0006141|C1709697|G0000000|C0199168|C0205099
"We excluded patients with distal tumor requiring anastomosis within 5 cm of the dentate line for technical reasons, patients with tumors larger than 6 cm or with tumor infiltration to the adjacent organs on sonography or CT, patients with previous abdominal operations near the field of the colorectal operation, patients who did not give consent to the procedure, and patients with intestinal obstruction or perforation.","We excluded patients distal tumor requiring anastomosis 5 cm dentate technical reasons, patients tumors larger 6 cm tumor infiltration adjacent organs sonography CT, patients previous abdominal operations field colorectal operation, patients consent procedure, patients intestinal obstruction perforation.",G0000000|C1554077|C0030705|C0205108|C0027651|G0000000|C0332853|G0000000|G0000000|G0000000|C0449851|C0392360|C0030705|C0027651|C0549177|G0000000|G0000000|C0027651|C0332448|C0205117|C0178784|C0041618|C0007673|C0030705|C0205156|C0000726|C0038895|C0440042|C0555952|C0543467|C0030705|C1511481|C0184661|C0030705|C0021853|C0028778|C0549099
"We excluded children who had signs of severe pneumonia or disease (cyanosis, convulsions, inability to drink, difficult to wake, severe malnutrition, stridor), other conditions requiring antibiotic treatment, clinically recognised congenital heart disease, chronic systemic disorders, a history of repeated wheezing or asthma, been hospitalised in the previous two weeks, taken antibiotics in the previous two days, measles within the previous month, or a history of penicillin allergy and those already enrolled in the study.","We excluded children signs severe pneumonia disease (cyanosis, convulsions, inability drink, difficult wake, severe malnutrition, stridor), conditions requiring antibiotic treatment, clinically recognised congenital heart disease, chronic systemic disorders, history repeated wheezing asthma, hospitalised previous weeks, antibiotics previous days, measles previous month, history penicillin allergy enrolled study.",G0000000|C1554077|C0008059|C0220912|C0205082|C0032285|C0012634|C0010520|C0036572|G0000000|C0452428|C0332218|C0442696|C0205082|C0162429|C0038450|C0012634|G0000000|C0003232|C0039798|G0000000|G0000000|C0009678|C0018787|C0012634|C0205191|C0205373|C0012634|C0019664|C0205341|C0043144|C0004096|G0000000|C0205156|C0439230|C0003232|C0205156|C0439228|C0025007|C0205156|C0332177|C0019664|C0030827|C0002111|G0000000|C0557651
Patients with one to three brain metastases of solid tumors (small-cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to adjuvant WBRT (30 Gy in 10 fractions) or observation (OBS).,Patients brain metastases solid tumors (small-cell lung cancer excluded) stable systemic disease asymptomatic primary tumors WHO performance status (PS) 0 2 treated complete surgery radiosurgery randomly assigned adjuvant WBRT (30 Gy 10 fractions) observation (OBS).,C0030705|C0006104|C0027627|C0205208|C0027651|C0700321|C0024109|C0006826|C1554077|C0205360|C0205373|C0012634|C0231221|C0205225|C0027651|G0000000|C0597198|C0449438|C0242397|G0000000|G0000000|C1522326|C0205197|C0038894|C0085203|G0000000|C1516050|C0001551|C1520143|C0450371|C0018408|C0450371|C1264633|C0302523|C2986870
"Exclusion criteria were high reported intake of DHA foods (i.e., more than one fish meal per week or use of any supplements that contain DHA), concurrent inflammatory, vascular, or metabolic disease, including diabetes, polycystic ovary disease, collagen vascular disease, inflammatory bowel disease, or infection, and any plans to leave the area.","Exclusion criteria reported intake DHA foods (i.e., fish meal week supplements DHA), concurrent inflammatory, vascular, metabolic disease, including diabetes, polycystic ovary disease, collagen vascular disease, inflammatory bowel disease, infection, plans leave area.",C0680251|C0243161|C0684224|C1512806|C0142831|C0016452|C0683454|C0016163|C1998602|C0332174|C0242295|C0142831|C0205420|C0333348|C0005847|C0311400|C0012634|C0332257|C0011847|C3273362|C0029939|C0012634|C0009325|C0005847|C0012634|C0333348|C0021853|C0012634|C0009450|C0270724|G0000000|C0017446
